pyrroles has been researched along with Angiogenesis, Pathologic in 351 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (1.71) | 18.2507 |
| 2000's | 142 (40.46) | 29.6817 |
| 2010's | 201 (57.26) | 24.3611 |
| 2020's | 2 (0.57) | 2.80 |
| Authors | Studies |
|---|---|
| Aoyama, Y; Hayashi, Y; Imafuji, H; Kato, T; Kimura, M; Matsuo, Y; Mitsui, A; Morimoto, M; Murase, H; Ogawa, R; Omi, K; Saito, K; Takahashi, H; Takiguchi, S; Tsuboi, K; Ueda, G | 1 |
| Chen, CY; Lan, SJ; Lan, YH; Lin, YJ; Sheu, MJ; Wang, CCN | 1 |
| Al-Gayyar, MMH; Alattar, A; Alshaman, R; El-Kannishy, SMH; Hamdan, AM; Hassan, HM | 1 |
| Agarwal, N; Gill, DM; Vaishampayan, U | 1 |
| Huang, WH; Lee, AR; Lee, CI; Yang, TH | 1 |
| Andersen, LMK; Gaustad, JV; Rofstad, EK; Simonsen, TG | 1 |
| Fujishiro, M; Hayakawa, K; Hirai, T; Ikeda, K; Miyashita, T; Morimoto, S; Sekigawa, I; Takamori, K; Takasaki, Y; Tamura, N; Tsushima, H; Yamaji, K; Yoshida, Y | 1 |
| Aparna, HS; Atreya, HS; Harsha Raj, M; Rashmi, KC; Salimath, BP | 1 |
| Bill, R; Blank, A; Krebs, P; Marinoni, I; Normand, L; Pantasis, S; Perren, A; Tschan, MP; Wiedmer, T | 1 |
| Goto, K; Hayashi, T; Inoue, S; Kitadai, Y; Kitano, H; Matsubara, A; Sentani, K; Shinmei, S; Teishima, J; Yasui, W; Yuge, R | 1 |
| Carillio, G; Costanzo, R; Daniele, G; Manzo, A; Montanino, A; Morabito, A; Normanno, N; Perrone, F; Piccirillo, MC; Rocco, G; Sandomenico, C | 1 |
| Bullova, P; Cougnoux, A; Kopacek, J; Marzouca, G; Pacak, K | 1 |
| Adelaiye-Ogala, R; Arisa, S; Arrington, J; Buck, M; Budka, J; Chintala, S; Ciamporcero, E; Damayanti, NP; Draetta, GF; Elbanna, M; Ferris, M; Hancock, B; Hollenhorst, P; Hsu, CC; Irudayaraj, J; Keilhack, H; Kota, J; McCarthy, BP; Miles, KM; Orillion, A; Persohn, SA; Pettazzoni, P; Pili, R; Radovich, M; Seshadri, M; Shen, L; Tao, WA; Territo, PR; Zang, Y | 1 |
| Albersen, M; Beuselinck, B; Couchy, G; de Reynies, A; Job, S; Laguerre, B; Lerut, E; Meiller, C; Méjean, A; Oudard, S; Patard, JJ; Rioux-Leclercq, N; Schöffski, P; Verbiest, A; Verkarre, V; Zucman-Rossi, J | 1 |
| Berry, GJ; Goronzy, JJ; Tian, L; Watanabe, R; Weyand, CM; Zhang, H | 1 |
| Cao, YW; Dong, Z; Guo, L; Kang, EH; Liu, Y; Niu, HT; Wang, YH; Zhang, W | 1 |
| Andersen, LMK; Gaustad, JV; Hauge, A; Rofstad, EK; Simonsen, TG; Wegner, CS | 1 |
| Alcazar, C; Ding, S; Hou, L; Huang, NF; Joshi, P; Kawamura, M; Kim, M; Shrager, J; Strassberg, Z; Tang, S; Woo, YJ; Yang, G | 1 |
| Bommu, UD; Konidala, KK; Pabbaraju, N | 1 |
| Baulin, V; Busser, B; Coll, JL; Couvet, M; Gilson, P; Henry, M; Hurbin, A; Josserand, V; Lafanechère, L; Mahuteau-Betzer, F; Orlowska, A; Vanwonterghem, L; Vollaire, J; Werner, M | 1 |
| Amato, LB; Baldassarre, M; Bridgeman, VL; Columbaro, M; Cossarizza, A; De Luise, M; Feichtinger, RG; Foriel, S; Gasparre, G; Gibellini, L; Girolimetti, G; Grifoni, D; Iommarini, L; Kofler, B; Kurelac, I; Leone, G; Malanchi, I; Ombrato, L; Porcelli, AM; Ragazzi, M; Sollazzo, M; Umesh Ganesh, N; Vatrinet, R; Vidali, S; Vidone, M | 1 |
| Damarla, M; Damico, RL; Hassoun, PM; Johnston, L; Kolb, TM; Peloquin, GL | 1 |
| Mankal, P; O'Reilly, E | 1 |
| Jiang, XL; Luo, CL; Wu, XH; Zhang, Y | 1 |
| Cassinelli, G; Cominetti, D; Favini, E; Lanzi, C; Penco, S; Petrangolini, G; Pisano, C; Tortoreto, M; Vlodavsky, I; Zaffaroni, N; Zunino, F | 1 |
| Bydlowski, SP; Chierice, GO; Ferreira, AK; Filho, OM; Freitas, VM; Levy, D; Maria, DA; Rici, RE; Ruiz, JL | 1 |
| Bisht, S; Brossart, P; Feldmann, G | 1 |
| Akerman, S; Barber, PR; Bjorndahl, M; Daniel, RA; Evans, H; Fisher, M; Harris, S; Kanthou, C; Lefley, D; Lunt, SJ; Prise, VE; Reyes-Aldasoro, CC; Tozer, GM; Vojnovic, B; Williams, LJ | 1 |
| Chai, ZT; Gao, DM; Kong, LQ; Lu, L; Sun, HC; Tang, ZY; Wang, L; Wang, WQ; Wu, WZ; Xu, HX; Zhang, JB; Zhang, W; Zhu, XD; Zhuang, PY | 1 |
| Choorapoikayil, S; de Bruin, A; den Hertog, J; Kers, R; Weijts, B | 1 |
| Dokduang, H; Juntana, S; Khuntikeo, N; Loilome, W; Namwat, N; Riggins, GJ; Techasen, A; Yongvanit, P | 1 |
| Francois, R; Hochwald, SN; Iyer, R; Seshadri, M; Zajac-Kaye, M; Zhang, J | 1 |
| Ancukiewicz, M; Catalano, OA; Duda, DG; Hayano, K; Jain, RK; Jiang, T; Sahani, DV; Zhu, AX | 1 |
| Bozzi, F; Casali, PG; Cominetti, D; Gronchi, A; Libertini, M; Messina, A; Morosi, C; Negri, T; Palassini, E; Pilotti, S; Stacchiotti, S; Tamborini, E; Tortoreto, M; Zaffaroni, N | 1 |
| Goh, V; Gore, M; Juttla, JK; Larkin, JM; Nathan, PD; Reynolds, AR; Thompson, VL; Vasudev, NS | 1 |
| Bremer, C; Budny, T; Hahnenkamp, A; Heindel, W; Persigehl, T; Remmele, S; Ring, J; Schwartz, LH; Spiegel, HU; Stoeppeler, S | 1 |
| Fujita, K; Hatano, K; Kawashima, A; Nakai, Y; Nakata, W; Nonomura, N; Sato, M; Takayama, H; Uemura, M; Yoshida, T | 1 |
| Dornbusch, J; Erdmann, K; Froehner, M; Fuessel, S; Meinhardt, M; Wirth, MP; Wolff, I; Zacharis, A; Zastrow, S | 1 |
| Kowalewicz-Kulbat, M; Lawnicka, H; Melen-Mucha, G; Motylewska, E; Niedziela, A; Sicinska, P; Stepien, H | 1 |
| Bellmunt, J; Pons, F | 1 |
| Fukatsu, A; Gotoh, M; Hattori, R; Kuroda, M; Kuwahara, K; Morikawa, T; Sassa, N; Shimoyama, Y; Shiroki, R; Tsuzuki, T; Yoshino, Y | 1 |
| Aghebati-Maleki, L; Baradaran, B; Shahneh, FZ; Zamani, F | 1 |
| Bampi, VF; Da Silva, JL; De Oliveira, LB; Gomes, CF | 1 |
| Chen, H; Hou, W; Rojas, J; Sampath, P; Thorne, SH | 1 |
| Czabanka, M; Parmaksız, G; Vajkoczy, P; Vinci, M | 1 |
| Jia, B; Liu, H; Liu, Z; Ma, T; Shi, J; Sun, X; Wang, F; Wu, Y; Yu, X; Zhao, H | 1 |
| Giddabasappa, A; Goodman, J; Lappin, PB; Lee, J; Levkoff, T; Li, G; Nichols, T; Painter, CL; Pascual, B; Simmons, B; Xie, Z; Yan, Z; Zhang, CC; Zhang, Q | 1 |
| Devasahayam, N; Krishna, MC; Lizak, MJ; Matsumoto, S; Matsuo, M; Merkle, H; Mitchell, JB; Morris, HD; Munasinghe, JP; Saito, K; Suburamanian, S; Takakusagi, Y; Yasukawa, K | 1 |
| Ambrosetti, D; Amiel, J; Gastaud, L; Grépin, R; Marsaud, A; Pagès, G; Pedeutour, F | 1 |
| Follana, P; François, E; Gugenheim, J; Saada, E; Saint Paul, MC | 1 |
| Abdel-Aziz, AK; Abdel-Naim, AB; El-Demerdash, E; Elgendy, M; Shouman, S | 1 |
| Blosser, W; Stancato, L; Stewart, J; Swearingen, ML; Tate, CM; Vakana, E; Wyss, LV | 1 |
| Calero, R; Johnsen, JI; Morchon, E; Serrano, R | 1 |
| Al Rawashdeh, W; Arns, S; Ehling, J; Gremse, F; Kiessling, F; Knüchel-Clarke, R; Kray, S; Lederle, W; Spöler, F | 1 |
| Aguilera, O; Borrero-Palacios, A; Caramés, C; Casado, V; Chamizo, C; Cristóbal, I; del Puerto-Nevado, L; García-Foncillas, J; Madoz-Gúrpide, J; Martínez-Useros, J; Rincón, R; Rodríguez-Remírez, M; Rojo, F; Rubio, G; Vega, R; Zazo, S | 1 |
| Abe, S; Higaki, K; Kimura, T; Ogawara, K; Un, K; Yoshizawa, Y | 1 |
| Agrawal, V; Kim, J; Kim, K; Kim, YM; Kwon, YG; Lee, K; Lee, S; Park, H; Suh, YG | 1 |
| Anouar, Y; Baudin, E; Denorme, M; Dubessy, C; Gonzalez, BJ; Roux, C; Yon, L | 1 |
| Blacher, S; Calligaris, D; Cimino, J; De Pauw, E; De Tullio, P; Debois, D; Mari, B; Mazzucchelli, G; Noel, A; Paye, A; Primac, I; Sounni, NE; Truong, A | 1 |
| Choe, MS; Ha, JY; Jung, HR; Kim, BH; Kim, CI; Park, CH; Sohn, JC | 1 |
| Anderson, K; Azarian, S; Buchanan, N; Cepeda, R; Cobb, JS; Cook, F; Crowley, M; De Erkenez, A; Etemad-Gilbertson, B; Fassbender, E; Giza, S; Gounarides, J; Huang, Q; Jaffee, B; Jensen, A; Liao, SM; Meredith, E; Mogi, M; Poor, S; Qiu, Y; Rao, C; Shen, S; Woolfenden, A; Xu, Y; Yang, X; Yin, H; Zhou, J | 1 |
| Adelaiye, R; Attwood, K; Ciamporcero, E; Conroy, D; Gillard, B; Kuhnert, F; Lalani, AS; Miles, KM; Pili, R; Seshadri, M; Shen, L; Sotomayor, P; Thurston, G | 1 |
| de Gramont, A; Dos Santos, C; Faivre, S; Raymond, E; Sebbagh, S; Serova, M; Slimane, K; Tijeras-Raballand, A | 1 |
| Aarts, MJ; Hamming, L; Joosten, SC; Soetekouw, PM; Tjan-Heijnen, VC; van Engeland, M; Veeck, J | 1 |
| Buchfelder, M; Eyüpoglu, IY; Fan, Z; Ghoochani, A; Hatipoglu, G; Hock, SW; Savaskan, NE; Sehm, T; Weiss, R | 1 |
| Bianchi, C; Chu, LM; Dalal, RS; Elmadhun, NY; Sabe, AA; Sadek, AA; Sellke, FW | 1 |
| Cagnon, VH; Hetzl, AC; Kido, LA; Montico, F | 1 |
| Bessho, H; Huang, D; Iwamura, M; Matsumoto, K; Ong, CK; Siew, EY; Tan, J; Tan, SY; Teh, BT; Wong, B | 1 |
| Hennink, WE; Hiemstra, C; Kazazi-Hyseni, F; Kiessling, F; Kok, RJ; Lammers, T; Ramazani, F; Steendam, R; Storm, G; Van Nostrum, CF | 1 |
| Berndsen, RH; Bonvin, D; Dyson, PJ; Griffioen, AW; Nowak-Sliwinska, P; Scherrer, E; Weiss, A; Wong, TJ | 1 |
| Iqbal, Y; Malik, MF; Riaz, SK | 1 |
| Castricum, KC; Griffioen, AW; Honeywell, R; Kleibeuker, EA; Slotman, BJ; Ten Hooven, MA; Thijssen, VL; Verheul, HM | 1 |
| Calvo, A; Diaz, R; Manrique, I; Nguewa, PA; Redrado, M | 1 |
| Bobrzyk, M; Chronowska, J; Kukla, U; Madej, P; Okopień, B; Łabuzek, K | 1 |
| Annaratone, L; Brossa, A; Bussolati, B; Camussi, G; Grange, C; Mancuso, L; Mazzone, M; Satolli, MA | 1 |
| Cui, CH; Duda, DG; Jain, RK; Jeong, HS; Jones, D; Liao, S; Padera, TP; Wattson, DA; Willett, CG | 1 |
| Demlova, R; Hezova, R; Kovarikova, A; Merhautova, J; Poprach, A; Radova, L; Slaby, O; Svoboda, M; Vyzula, R | 1 |
| Huang, J; Ma, J; Mu, X; Qin, Y; Wu, G; Xu, S; Yang, K; Zhang, Z; Zhou, H | 1 |
| He, S; Shen, G; Wang, Y; Yin, T | 1 |
| Cao, Y; Cao, Z; Chen, X; Hosaka, K; Jensen, L; Liu, Y; Sun, Y; Wang, J; Yang, H; Zhuang, R | 1 |
| Cohen, EE; Fleming, GF; Harris, PJ; Janisch, L; Karovic, S; Karrison, TG; Levine, MR; Maitland, ML; O'Donnell, PH; Polite, BN; Ratain, MJ | 1 |
| Bjarnason, GA; Butz, H; Dharsee, M; Ding, Q; Evans, KR; Khella, HWZ; Kupchak, P; Latif, A; Lianidou, E; Pasic, MD; Rotondo, F; Yousef, GM | 1 |
| Kleibeuker, EA; Slotman, BJ; Ten Hooven, MA; Thijssen, VL; Verheul, HM | 1 |
| Blaes, J; Broggini, T; Czabanka, M; Harms, C; Harms, U; Mueller, S; Stange, L; Thomé, C; Vajkoczy, P; Weiler, M; Wick, W; Wüstner, M | 1 |
| Auberger, P; Belaid, A; Benhida, R; Colosetti, P; Cormerais, Y; Dufies, M; Giuliano, S; Grépin, R; Lacas-Gervais, S; Martin, A; Mazure, NM; Mograbi, B; Pagès, G; Parola, J | 1 |
| Bédouet, L; Jubeli, E; Labarre, D; Laurent, A; Moine, L; Pascale, F; Saint-Maurice, JP; Slimani, K; Yagoubi, N | 1 |
| Bridgeman, VL; Foo, S; Frentzas, S; Gore, M; Larkin, J; Nathan, MR; Nathan, PD; Powles, T; Preece, N; Reynolds, AR; Springer, CJ; Vasudev, NS; Vermeulen, PB; Wan, E; Welti, JC | 1 |
| Crawford, K; Dusing, M; Frischer, JS; Knod, JL | 1 |
| Chen, C; Li, G; Liu, FK; Liu, JY; Shen, L; Wu, GN; Wu, XY; Wu, ZF; Xu, H; Yao, XQ | 1 |
| Anckaert, E; Baurain, JF; De Brakeleer, S; De Grève, J; De Mey, J; Decoster, L; Majois, F; Neyns, B; Rorive, A; Rottey, S; Vande Broek, I | 1 |
| Atri, M; Bjarnason, GA; Burns, PN; Hudson, JM; Milot, L; Moshonov, H; Sinaei, M; Williams, R | 1 |
| Avoli, M; Benini, R; Khoja, Z; Roth, R; Wintermark, P | 1 |
| Cui, C; Hardwick, JC; Hawinkels, LJ; Heijkants, RC; Oudt, CH; Paauwe, M; Sier, CF; Theuer, CP; van Pelt, GW | 1 |
| Alexandre, J; Arrondeau, J; Blanchet, B; Boudou-Rouquette, P; Bretagne, M; Cabanes, L; Cessot, A; Chahwakilian, A; Coriat, R; Goldwasser, F; Huillard, O; Orvoen, G; Thomas-Schoemann, A; Tlemsani, C | 1 |
| Benedetto, P; Flores, A; Kovacs, K; Kwon, D; Merchan, JR; Montero, AJ; Rocha-Lima, C; Trent, JC | 1 |
| Dornbusch, J; Fuessel, S; Gottschalk, A; Grimm, MO; Junker, K; Klug, SJ; Meinhardt, M; Obaje, A; Ohlmann, CH; Schoffer, O; Walter, M; Wirth, MP; Zacharis, A; Zastrow, S | 1 |
| Barclay, JL; Gobe, GC; Johnson, DW; Li, L; Morais, C; Ng, KL; Oliver, K; Rajandram, R; Samaratunga, H; Small, DM; Vesey, DA; Wood, S | 1 |
| Hwang, IG; Ji, JH; Lee, SJ; Lim, DH; Lim, HY; Lim, SH; Oh, SY; Park, SH; Yi, JH | 1 |
| Annaert, P; Darville, N; De Jonghe, S; De Meulder, M; Mariën, D; Rossenu, S; Sterkens, P; Van den Mooter, G; van Heerden, M; Vermeulen, A; Vynckier, A | 1 |
| Bono, P; Joensuu, H; Lampinen, A; Mirtti, T; Rautiola, J; Ristimäki, A; Saharinen, P | 1 |
| Andrikou, K; Bianconi, M; Bittoni, A; Burattini, L; Cascinu, S; Del Prete, M; Faloppi, L; Giampieri, R; Loretelli, C; Montironi, R; Scartozzi, M; Zizzi, A | 1 |
| Alimzhanov, M; Alsop, DC; Atkins, MB; Bhasin, MK; Bhatt, RS; Callea, M; Khanna, P; Kumar, R; Mier, JW; Pearsall, RS; Signoretti, S; Solban, N; Song, J; Wang, X | 1 |
| Ait-Oudhia, S; Fetterly, G; Groman, A; Iyer, R; Mager, DE; Pokuri, V; Tomaszewski, G; Zagst, P | 1 |
| Papaxoinis, G; Saif, MW; Syrigos, K | 1 |
| Anta, H; Fillat, C; Gibert, J; Guerrero, PE; Iglesias, M; José, A; Martínez-Bosch, N; Moreno, M; Munné-Collado, J; Navarro, P; Orozco, CA; Vinaixa, J; Viñals, F | 1 |
| Bieche, I; Bousquet, G; Bryan, BA; de Gramont, A; Dos Santos, C; Faivre, S; Gapihan, G; Janin, A; Lopez, A; Martinet, M; Mitchell, DC; Neuzillet, C; Raymond, E; Riveiro, ME; Serova, M; Tijeras-Raballand, A | 1 |
| Barnard, J; Diaz-Montero, CM; Finke, JH; Lindner, DJ; Mao, FJ; Parker, Y; Pink, JJ; Rini, BI; Zamanian-Daryoush, M | 1 |
| Hu, J; Li, C; Setrerrahmane, S; Xu, H; Yassin, S | 1 |
| Salomon, RG; Tomko, N; Wang, WR; Wang, X; Wang, Y; Wangf, B; Wu, C; Zhu, J | 1 |
| Capozzi, M; DE Divitiis, C; Ottaiano, A; Romano, GM; Tafuto, S; Tatangelo, F; VON Arx, C | 1 |
| Bilecz, A; Bridgeman, VL; Daley, F; Dome, B; Dvorak, HF; Foo, S; Frentzas, S; Gore, M; Hegedus, B; Hoetzenecker, K; Kerbel, RS; Kostaras, E; Kuczynski, EA; Larkin, J; Nathan, MR; Paku, S; Renyi-Vamos, F; Reynolds, AR; Schweiger, T; Vasudev, NS; Vermeulen, PB; Wan, E | 1 |
| Bai, R; Bastian, A; Choudhary, S; Gangjee, A; Hamel, E; Ihnat, MA; Pavana, RK | 1 |
| Angelini, S; Biasco, G; Gatto, L; Hrelia, P; Nannini, M; Pantaleo, MA; Ravegnini, G; Sammarini, G; Saponara, M; Simeon, V; Urbini, M; Venturoli, N; Zenesini, C | 1 |
| Kurzrock, R; Stewart, DJ | 1 |
| Arosio, D; Battistini, L; Bianchini, F; Calorini, L; Portioli, E; Pupi, A; Sartori, A; Vacondio, F; Zanardi, F | 1 |
| Afshar, M; Bardoli, AD; Miscoria, M; Pirrie, S; Porfiri, E; Stubbs, C; Wheeley, I | 1 |
| Chen, B; Chen, F; He, W; Hu, J; Liu, X; Wang, L; Xu, Z; Zhang, L | 1 |
| Antón-Aparicio, LM; Leon, LA | 1 |
| Gong, P; Qin, M; Tian, Y; Wang, L; Yan, S; Zhang, H; Zhao, Y | 1 |
| Cheng, S; Dong, X; Gu, Q; Li, L; Lin, X; Liu, F; Liu, J; Sun, H; Sun, S; Wang, Y; Yao, N; Yao, Z; Zhang, D | 1 |
| Del Conte, G; Guibal, A; Rüegg, C; Sessa, C | 1 |
| Chu, ZH; Luo, XJ; Zeng, QL; Zhou, K | 1 |
| Cao, R; Cao, Y; Hauptmann, G; Jensen, LD; Söll, I | 1 |
| Chen, L; Feng, YL; Huang, XY; Li, WC; Li, YP; Liu, DS; Ou, XM; Wang, K; Wang, T; Wang, X; Wen, FQ; Zhang, SF | 1 |
| Arrigoni, C; Denlinger, R; Evering, W; Heward, JK; Kim, TW; Patyna, S; Terron, A; Turnquist, SE; Vonderfecht, SL | 1 |
| Antonaci, S; Fransvea, E; Giannelli, G; Mazzocca, A | 1 |
| Awada, AH; Hatoum, HA; Ishak, RS; Otrock, ZK; Shamseddine, AI | 1 |
| Izzedine, H; Massard, C; Soria, JC | 1 |
| Carter, DE; Karlik, SJ; Roscoe, WA; Welsh, ME | 1 |
| Busby, B; Covington, J; Gu, JW; Johnson, JW; Young, E | 1 |
| Du, Y; Figlin, R; Herrmann, A; Xin, H; Yu, H; Zhang, C | 1 |
| Bjarnason, GA; Christensen, JG; Cruz-Munoz, W; Ebos, JM; Kerbel, RS; Lee, CR | 1 |
| Andreadis, C; Kontovinis, LF; Kortsaris, AH; Mouratidou, D; Papazisis, KT; Touplikioti, P | 1 |
| Farace, F; Geoerger, B; Lagodny, J; Rössler, J; Taylor, M; Vassal, G | 1 |
| Borgman, CL; Brandstetter, KA; Chirieac, LR; Gandhi, L; Li, D; McDermott, U; McNamara, KL; Padera, RF; Settleman, JE; Wong, KK | 1 |
| Armand, JP; Domont, J; Lassau, N; Le Cesne, A; Massard, C; Soria, JC | 1 |
| Arbustini, E; Gambarin, FI | 1 |
| Caruthers, SD; Lanza, GM; Wickline, SA; Williams, TA; Winter, PM; Zhang, H | 1 |
| Hamada, Y; Shibata, A; Tahara, M; Yamaguchi, S | 1 |
| Maitland, ML; Snider, KL | 1 |
| Calderan, L; Daducci, A; Degrassi, A; Farace, P; Galiè, M; Marzola, P; Merigo, F; Nicolato, E; Pesenti, E; Sbarbati, A | 1 |
| Gall, P; Hengerer, A; Huppert, J; Kiessling, F; Kiselev, V; Lederle, W; Palmowski, M; Semmler, W; Strecker, R; Taupitz, M; Woenne, EC; Zwick, S | 1 |
| Baruchel, S; Chong, AL; Irwin, MS; Kaplan, DR; Marrano, P; Smith, KM; Stempak, D; Thorner, PS; Yeger, H; Zhang, L | 1 |
| Capellà, G; Casanovas, O; Castillo-Avila, W; Condom, E; Garcia Del Muro, X; Germà, JR; Mora, J; Piulats, JM; Vidal, A; Villanueva, A; Viñals, F | 1 |
| Billemont, B; Kelly, RJ; Rixe, O | 1 |
| Burkitt, K; Chun, SY; Dang, DT; Dang, LH | 1 |
| Shibuya, M | 1 |
| Boterberg, T; Casneuf, VF; Delrue, L; Demetter, P; Peeters, M; Van Damme, N | 1 |
| Cortés-Funes, H | 1 |
| Budd, S; Byfield, G; Geisen, P; Hartnett, ME; Martiniuk, D | 1 |
| Amura, CR; Barry, NP; Brodsky, KS; Doctor, RB; McWilliams, RR | 1 |
| Antonaci, S; Fransvea, E; Giannelli, G; Lavezzari, G; Mazzocca, A | 1 |
| Abrams, J; Al-Bashir, AK; Haacke, EM; Hillman, GG; Katkuri, Y; Li, M; Patel, AD; Singh-Gupta, V; Yunker, CK; Zhang, H | 1 |
| Chandramouli, GV; Hyodo, F; Krishna, MC; Matsumoto, K; Matsumoto, S; Mitchell, JB; Munasinghe, JP | 1 |
| Chang, AP; Choo, SP; Chow, PK; Chung, AY; Huynh, H; Jin, Y; Koong, HN; Ngo, VC; Ong, HS; Ong, LC; Poon, D; Song, IC; Soo, KC; Thng, CH; Toh, HC; Zheng, L | 1 |
| Blann, AD; Goon, PK; Jaumdally, RJ; Lip, GY; Varma, C | 1 |
| Chun, MG; Golub, TR; Hanahan, D; Libutti, SK; Lu, J; Nakakura, EK; Olson, P; Shai, A; Wang, Y; Zhang, H | 1 |
| Garnock-Jones, KP; Keating, GM | 1 |
| Andrade, SP; Araújo, FA; Mendes, JB; Rocha, MA | 1 |
| Faivre, S; Hammel, P; Raymond, E; Ruszniewski, P | 1 |
| Baba, M; Hiramatsu, Y; Kamiya, K; Kawabata, T; Kikuchi, H; Konno, H; Ohta, M; Tanaka, T; Yamamoto, M | 1 |
| Peter, S; Rohde, D; Tong, TQ | 1 |
| Ding, Y; Huang, D; Li, Y; Luo, WM; Qian, CN; Snider, J; Teh, BT; Vandenbeldt, K; Zhang, ZF | 1 |
| Guillén-Ponce, C; Mena, AC; Pulido, EG | 1 |
| Abdulkarim, B; Aghi, M; Chahal, M; Christensen, JG; Famulski, K; Graham, K; Jacques, A; Lesniak, D; Murray, D; Sabri, S; Xu, Y | 1 |
| Cascone, T; Heymach, JV; Nilsson, MB; Saigal, B; Wu, HK; Xu, L; Zage, PE; Zeng, L; Zweidler-McKay, PA | 1 |
| Chen, SH; Eisenstein, S; Fu, S; Kao, J; Ko, EC; Sikora, AG | 1 |
| Ayllon, J; Barrascout, E; Cuenod, CA; Elaidi, R; Medioni, J; Mejean, A; Oudard, S; Scotte, F; Tartour, E | 1 |
| Deville, JL; Duffaud, F; Huynh, T; Salas, S | 1 |
| Banach-Petrosky, W; Biswas, S; Ganapathy, V; Ge, R; Grazioli, A; Kang, Y; Lonning, S; McPherson, J; Mundy, GR; Reiss, M; Xie, W; Yingling, JM | 1 |
| Gu, JW; Huang, M; Miele, L; Tucker, KB; Wells, J; Young, E | 1 |
| Figlin, RA; Pal, SK; Yu, H | 1 |
| Castelo, B; Espinosa, E; Pinto, A; Redondo, A; Zamora, P | 1 |
| Borden, EC; Byzova, TV; Kerr, BA; Malinin, NL; Merkulova, AA; Podrez, EA; Salomon, RG; Tischenko, M; West, XZ | 1 |
| Bauerschlag, DO; Egberts, JH; Jonat, W; Kalthoff, H; Maass, N; Meinhold-Heerlein, I; Schem, C; Tiwari, S; Weigel, MT | 1 |
| Christensen, JG; Esparza, CO; Feng, J; Hu-Lowe, DD; Lee, JH; Plumlee, PA; Shojaei, F; Simmons, BH; Stewart, AE; Wong, A | 1 |
| Denison, FC; Gray, GA; Maldonado-Pérez, D; Moyes, AJ | 1 |
| Andersen, JL; Andersson, M; Kamby, C; Nielsen, DL | 1 |
| Fisher, PB; Sarkar, D; Wang, XY | 1 |
| Biessen, EA; Bot, I; Jukema, JW; Lankhuizen, IM; van Berkel, TJ | 1 |
| Choi, SH; Chung, JW; Im, SA; Jae, HJ; Jun, S; Kim, HC; Park, JH; Yamasaki, Y | 1 |
| Boulton, ME; Cai, J; Han, S; Law, B; Liao, D; Qing, R | 1 |
| Carroll, AR; Coleman, RL; Sood, AK | 1 |
| Amatulli, M; Claros, N; Corcoran, E; Duignan, IJ; Iacolina, M; Pennello, A; Plym, MJ; Samakoglu, S; Schwartz, J; Surguladze, D; Tonra, JR; Witte, L; Youssoufian, H | 1 |
| Claes, A; Hamans, BC; Heerschap, A; Jeuken, JW; Leenders, WP; Navis, AC; Wesseling, P | 1 |
| Baryshnikov, A; Grigorieva, I; Lichinitser, M; Solomko, E; Stepanova, E; Vartanian, A | 1 |
| Blairvacq, M; Karuso, P; Loa-Kum-Cheung, WL; Meijer, L; Nakao, Y; Parish, CR; Shengule, SR | 1 |
| Maráz, A | 1 |
| Banik, NL; Karmakar, S; Mohan, N; Ray, SK | 1 |
| Morimoto, J; Otsuki, Y; Shibata, MA; Tanaka, Y | 1 |
| Daignault, S; Dy, GK; Gadgeel, SM; Kalemkerian, GP; Ramnath, N; Schneider, BJ; Wozniak, AJ | 1 |
| Emanuel, S; Fairchild, C; Fargnoli, J; Fink, B; Gavai, A; Hammell, A; Henley, B; Hilt, C; Hunt, JT; Krishnan, B; Kukral, D; Lee, FY; Lewin, A; Malone, H; Norris, D; Oppenheimer, S; Vite, G; Wong, TW; Yu, C | 1 |
| Fousteris, M; Koutsourea, A; Lampropoulou, E; Manioudaki, M; Nikolaropoulos, S; Papadimitriou, E | 1 |
| Chen, FH; Chiang, CS; Fu, SY; Hong, JH; Jung, SM; Lee, CC; Tsai, CS; Wang, CC; Wen, CJ | 1 |
| Cunningham, D; Okines, AF; Reynolds, AR | 1 |
| Beelen, RH; Schilte, MN; Stavenuiter, AW; Ter Wee, PM | 1 |
| Katanasaka, Y; Kitamura, Y; Kodera, Y; Koizumi, F; Nishio, K; Tamura, T; Tsuda, H | 1 |
| Li, Z; Lin, S; Wang, X; Wei, Y; Yang, H; Zhao, C; Zhao, Y | 1 |
| Fukui, I; Hatake, K; Takahashi, S; Yonese, J; Yuasa, T | 1 |
| de Wijn, R; Flatmark, K; Fodstad, Ø; Folkvord, S; Rasmussen, H; Ree, AH; Saelen, MG | 1 |
| Choo, SP; Chow, PK; Chung, AY; Huynh, H; Ong, R; Soo, KC; Tai, WM; Toh, HC | 1 |
| Barré, L; Bernaudin, M; Delamare, J; Divoux, D; Marteau, L; Petit, E; Roussel, S; Sobrio, F; Toutain, J; Valable, S | 1 |
| Calcinaro, F; D'Agostino, M; Durante, C; Filetti, S; Moretti, S; Puxeddu, E; Rhoden, K; Russo, D; Sponziello, M; Tallini, G; Tamburrano, G; Voce, P | 1 |
| Yim, KL | 1 |
| Batra, S; Choudhuri, R; Devasahayam, N; Gadisetti, C; Krishna, MC; Matsumoto, S; Mitchell, JB; Munasinghe, JP; Saito, K; Subramanian, S; Yasui, H | 1 |
| Backer, JM; Backer, MV; Blankenberg, FG; Goris, MG; Hamby, CV; Levashova, Z | 1 |
| Anderson, KC; Podar, K | 1 |
| Fiedler, W; Wellbrock, J | 1 |
| Debus, J; Han, N; Huber, PE; Kleber, S; Lahn, M; Martin-Villalba, A; Peschke, P; Röhrich, M; Timke, C; Tuettenberg, J; Wirkner, U; Zhang, M | 1 |
| Reed, MW; Young, RJ | 1 |
| Al Hussaini, AA; Allegood, JC; Bogaard, HJ; Fadel, E; Farkas, D; Farkas, L; Guignabert, C; Humbert, M; Kraskauskas, D; Mizuno, S; Ruiter, G; Spiegel, S; Voelkel, NF; Vonk Noordegraaf, A | 1 |
| Choi, MJ; Hong, S; Hong, SS; Hong, SW; Jung, KH; Lee, H; Lee, HS; Zheng, HM | 1 |
| Kang, SG; Kim, SG; Lee, WH; Lee, YH; Lee, YS | 1 |
| Christensen, JG; Lappin, PB; Lee, JH; Shojaei, F; Simmons, BH | 1 |
| Cho, G; Kang, JS; Kang, MR; Kim, JK; Kim, YR; Lee, CK; Park, SB; Song, Y; Suh, JY | 1 |
| Andresen, CJ; Bagi, CM; Gebhard, DF | 1 |
| Boulanger, G; Edeline, J; Jouan, F; Martin, B; Oger, E; Patard, JJ; Rioux-Leclercq, N; Vigneau, C; Zerrouki, S | 1 |
| Döme, B; Török, S | 1 |
| Conley, SJ; Wicha, MS | 1 |
| Aebi, JD; Chapuis-Bernasconi, C; Dehmlow, H; Fischer, H; Juillerat-Jeanneret, L; Staedler, D | 1 |
| Bex, A; de Graaf, AMA; de Hoog, CLMM; de Jong, TAM; Griffioen, AW; Jonasch, E; Mans, LA; Nowak-Sliwinska, P; van Beijnum, JR; Vyth-Dreese, FA | 1 |
| Akiyama, S; Dat, le T; Goto, H; Hanibuchi, M; Kakiuchi, S; Kuramoto, T; Nishioka, Y; Sakaguchi, S; Sato, S; Sone, S; Van, TT; Yukishige, S | 1 |
| Aogi, K; Arioka, H; Fujii, H; Fujiwara, Y; Inoue, K; Ito, Y; Iwata, H; Saeki, T; Suzuki, Y; Takatsuka, Y; Toi, M; Tokuda, Y; Watanabe, T | 1 |
| Benavent, M; de Miguel, MJ; Garcia-Carbonero, R | 1 |
| Chung, AS; Ferrara, N; Finkle, D; Komuves, L; Kowanetz, M; Ngu, H; Peale, F; Wu, X; Zhuang, G | 1 |
| Chen, J; Jiang, R; Li, Z; Sun, L; Tian, Y; Wang, B; Wang, D; Wei, H; Yang, Z; Zhang, J | 1 |
| Blay, JY; Casali, PG; Cohen, DP; Demetri, GD; Garrett, CR; Goldstein, D; Harmon, CS; Huang, X; Hurwitz, HI; Le Cesne, A; Leyvraz, S; McArthur, GA; Paz-Ares, L; Pousa, AL; Schöffski, P; Shah, MH; Tassell, V; Verweij, J; Xu, QC | 1 |
| Awasthi, N; Ruan, W; Schwarz, MA; Schwarz, RE; Zhang, C | 1 |
| Andalib, S; Asadpoor, M; Doustar, Y; Garjani, A; Garjani, M; Khorrami, A; Maleki-Dizaji, N; Rezazadeh, H; Soraya, H; Ziaee, M | 1 |
| Braunfeld, J; Brekken, RA; Burrows, FJ; Carbon, JG; Kirane, A; Ostapoff, K; Schwarz, RE; Toombs, JE; Zaknoen, S | 1 |
| Kaklamani, V; Raffin, M; Reddy, S | 1 |
| Jing, C; Ning, J; Yuanjie, N | 1 |
| Gallo, JM; Lv, H; Ma'ayan, A; Mazloom, AR; Xu, H; Zhou, Q | 1 |
| Gaustad, JV; Leinaas, MN; Rofstad, EK; Simonsen, TG | 1 |
| de Groot, JF; Henry, V; Heymach, JV; Holmes, L; Liang, J; Piao, Y; Zurita, AJ | 1 |
| Pfister, C; Pfrommer, H; Roser, F; Tatagiba, MS | 1 |
| Amin, A; Badr El-Din, NK; Choi, SK; Kadowitz, P; Kevil, CG; Matrougui, K; Navar, LG; Osman-Elazeik, Y; Trebak, M | 1 |
| Abe, S; Araki, T; Fushimi, A; Higaki, K; Ishikawa, K; Kimura, T; Molema, G; Ogawara, K; Yoshizawa, Y | 1 |
| De Amici, M; Ganini, C; Giunta, V; Imarisio, I; Paglino, C; Porta, C; Quaglini, S; Sacchi, L | 1 |
| Iiri, T; Makita, N | 1 |
| Berlin, JD | 1 |
| Baker, CH; Bucana, CD; Fidler, IJ; Kedar, D; McCarty, MF; Tsan, R; Weber, KL | 1 |
| Hoekman, K; Kakkar, AK; Kostense, PJ; Kuenen, BC; Levi, M; Meijers, JC; Pinedo, HM; van Hinsbergh, VW | 1 |
| Baker, CH; Dinney, CP; Fidler, IJ; Kedar, D; Killion, JJ | 1 |
| Chu, E | 1 |
| Cherrington, J; Itokawa, T; Iwamoto, Y; Kuwano, M; McMahon, G; Nishioka, Y; Nokihara, H; Ono, M; Shibuya, M; Sone, S; Yamada, Y | 1 |
| Rosen, LS | 1 |
| Barraja, P; Beall, HD; Bunderson, M; Moody, CJ; Newsome, JJ; Swann, E; Tooke, JE; Whatmore, JL | 1 |
| Ellis, LM | 1 |
| Alileche, A | 1 |
| Bachelot, T; Blay, JY; Jouanneau, E | 1 |
| Bergers, G; Bergsland, E; Hanahan, D; Meyer-Morse, N; Song, S | 1 |
| Baselga, J; Cavalli, F; Conte, PF; Deplanque, G; Harris, AL; Hoekman, K; Huisman, H; Kuenen, BC; Madhusudan, S; Pfanner, E; Scigalla, P; Seeber, S; Tabernero, J | 1 |
| Fueller, T; Hummel, V; Rieckmann, P; Tonn, JC; Wagner, S | 1 |
| Abdollahi, A; Debus, J; Hahnfeldt, P; Han, X; Hlatky, L; Howlett, AR; Huber, PE; Krempien, R; Lipson, KE; Trinh, T; Weber, KJ | 1 |
| Bergers, G; Hanahan, D | 1 |
| Donnelly, E; Geng, L; Hallahan, DE; Himmelfarb, E; McMahon, G; Mendel, D; Schueneman, AJ; Tan, J | 1 |
| Barrios, RJ; Greenberg, NM; Huss, WJ | 1 |
| Hasselbalch, HC | 1 |
| Buckley, P; Doroshow, JH; Frankel, P; Galvin, I; Gandara, DR; Gosselin, R; Gumerlock, PH; Lara, PN; Lenz, HJ; Longmate, J; Mack, PC; Margolin, K; Meyers, FJ; Quinn, DI; Rao, J; Turrell, C; Valk, P; Wun, T | 1 |
| Karas, RH; Kimmelstiel, C; Pourati, I; Rand, W | 1 |
| Erber, R; Groth, G; Hammes, HP; Katsen, AD; Kerger, H; Menger, MD; Thurnher, A; Ullrich, A; Vajkoczy, P | 1 |
| Abdollahi, A; Bischof, M; Debus, J; Grone, HJ; Hahnfeldt, P; Han, X; Hlatky, L; Huber, PE; Klenke, F; Krix, M; Lipson, KE; Poerschke, D; Roth, A; Sckell, A; Zieher, H | 1 |
| Albitar, M; Anaissie, E; Cherrington, J; Cooper, M; Faderl, S; Garcia-Manero, G; Giles, FJ; Hannah, A; Kantarjian, H; Lancet, J; Morimoto, A; Stopeck, A; Tan, N; Zangari, M | 1 |
| Abrams, T; Calderan, L; Crescimanno, C; Degrassi, A; Farace, P; Giusti, A; Marzola, P; Murray, L; Nicolato, E; Osculati, F; Pesenti, E; Sbarbati, A; Terron, A | 1 |
| Fidler, IJ; Yokoi, K | 1 |
| Bönninghoff, R; Dono, R; Gretz, N; Keese, M; Magdeburg, R; Sturm, J; Vajkoczy, P; Zeller, R; Zhang, H | 1 |
| Dellian, M; Eichhorn, ME; Strieth, S | 1 |
| Gajewski, TF; Karczmar, G; Medved, M; Peterson, AC; Stadler, WM; Swiger, S | 1 |
| Bruns, CJ; Guba, M; Jauch, KW; Kleespies, A | 1 |
| Bevilacqua, G; Bocci, G; Boggi, U; Boschi, E; Campani, D; Danesi, R; Del Tacca, M; Esposito, I; Fasciani, A; Fioravanti, A; Marangoni, G; Mosca, F | 1 |
| Jiang, BH; Reed, E; Zheng, JZ; Zhong, XS | 1 |
| Abdollahi, A; Bischof, M; Debus, JU; Gong, P; Huber, PE; Lipson, KE; Stoffregen, C; Weber, KJ | 1 |
| Krystal, GW; Lipson, KE; Litz, J; Sakuntala Warshamana-Greene, G; Sulanke, G | 1 |
| Hanahan, D; Pietras, K | 1 |
| Fu, A; Geng, L; Hallahan, DE; Osusky, KL; Shyr, Y; Ye, F | 1 |
| Abbruzzese, JL; Davis, DW; Demetri, GD; Herbst, RS; Heymach, JV; McConkey, DJ; Rashid, A; Raut, CP; Shen, Y; Stadler, WM; Takamori, R; Wen, S; Xiong, HQ | 1 |
| Capelle, HH; Erber, R; Farhadi, MR; Ullrich, A; Vajkoczy, P | 1 |
| Fu, M; Guo, S; Li, S; Liang, X; Lin, C; Lu, H; Wu, M; Zhang, X; Zheng, Z | 1 |
| Angermayr, B; Bosch, J; Fernandez, M; Garcia-Pagan, JC; Mejias, M; Rodés, J | 1 |
| Donnelly, EF; Fleischer, AC; Geng, L; Hallahan, DE; Niermann, KJ; Schueneman, AJ | 1 |
| Calderan, L; Crescimanno, C; Degrassi, A; Farace, P; Giusti, A; Marzola, P; Nicolato, E; Osculati, F; Pesenti, E; Sandri, M; Sbarbati, A; Terron, A | 1 |
| Schiller, JH; Wakelee, HA | 1 |
| Elitzsch, A; Laschke, MW; Menger, MD; Vajkoczy, P; Vollmar, B | 1 |
| Kitagawa, Y; Kitajima, M; Kubota, T; Nakamura, T; Ozawa, S; Ueda, M | 1 |
| Fu, A; Hallahan, DE; Huamani, J; Kim, DW | 1 |
| Berghaus, A; Dellian, M; Eichhorn, ME; Jonczyk, A; Strieth, S; Sutter, A | 1 |
| Bani, MR; Borsotti, P; Cassis, L; Eccles, SA; Garofalo, A; Giavazzi, R; Naumova, E; Riccardi, E; Scanziani, E; Ubezio, P | 1 |
| Abraldes, JG; Groszmann, RJ; Haq, O; Iwakiri, Y; Loureiro-Silva, M; Sessa, WC | 1 |
| Gasparini, G; Longo, R; Sarmiento, R | 1 |
| Cabebe, E; Wakelee, H | 2 |
| Jiang, XT; Tao, HQ; Zou, SC | 1 |
| Burstein, HJ; Rugo, HS; Sledge, GW | 1 |
| Rini, BI | 3 |
| Miroglu, C; Silay, MS | 1 |
| Heldin, CH; Ostman, A | 1 |
| Auersperg, N; Cosin, J; Dings, RP; Ramakrishnan, S; Schumacher, JJ; Subramanian, IV | 1 |
| Angele, MK; Bruns, CJ; Eichhorn, ME; Jauch, KW; Kleespies, A | 1 |
| Blay, JY | 1 |
| Baz, RC; Bukowski, RM; Choueiri, TK; Elson, P; Garcia, JA; Golshayan, AR; Khasawneh, M; Rini, BI; Usman, S; Wood, L | 1 |
| Grosicka, A; Grosicki, S; Hołowiecki, J | 1 |
| Chouhan, JD; Grabinski, JL; Lai, PH; Oramasionwu, CU; Zamarripa, DE | 1 |
| Christensen, JG; de Boüard, S; Gauduchon, P; Guillamo, JS; Herlin, P; Lemoisson, E; Raymond, E | 1 |
| Billemont, B; Rixe, O; Thibault, F | 1 |
| Bodrogi, I | 1 |
| Hayes, DF; Miller, K; Sledge, G | 1 |
| Bello, C; DePrimo, SE | 1 |
| Christensen, JG | 1 |
| Armand, JP; Mir, O; Ropert, S | 1 |
| Billemont, B; Izzedine, H; Méric, JB; Rixe, O; Sultan-Amar, V; Taillade, L | 1 |
| Abdul-Karim, FW; Dowlati, A; Duerk, J; Fu, P; Hanks, S; Hartman, P; Hoppel, C; Ivy, P; Jesberger, JA; Lewin, J; McCrae, K; Overmoyer, B; Persons, M; Radivoyevitch, T; Remick, SC; Robertson, K; Shenk, R; Silverman, P; Wasman, JK; Ziats, NP | 1 |
| Alba, E; Medina, MA; Quesada, AR | 1 |
| Culine, S; Pouessel, D | 1 |
| Anderson, KC; Brahmandam, M; Chauhan, D; Hideshima, T; Munshi, N; Palladino, MA; Podar, K; Richardson, P; Singh, A | 1 |
| Culine, S; Patard, JJ; Pouessel, D; Verhoest, G | 1 |
| Alexander, HR; Blansfield, JA; Caragacianu, D; Libutti, SK; Lorang, D; Morita, SY; Muller, G; Royal, RE; Schafer, P; Stirling, D; Tangrea, MA | 1 |
| Anand-Apte, B; Crabb, JW; Ebrahem, Q; Gu, X; Lu, L; Renganathan, K; Salomon, RG; Sears, J; Vasanji, A | 1 |
| Dudek, AZ; Mulamalla, K; Truskinovsky, AM | 1 |
| Giordano, S; Petrelli, A | 1 |
| Gallo, JM; Guo, P; Zhou, Q | 1 |
| Abdollahi, A; Debus, J; Hauser, K; Huber, PE; Lipson, KE; Roth, A; Timke, C; Weber, KJ; Zieher, H | 1 |
| Abbruzzese, JL; Chiao, PJ; Fleming, JB; Ishiyama, S; Melisi, D; Sclabas, GM; Tortora, G; Xia, Q | 1 |
| Gaumann, A; Geissler, EK; Lang, SA; Mori, A; Moser, C; Schachtschneider, P; Schlitt, HJ; Stoeltzing, O; Zimmermann, J | 1 |
| Lee, CB; Socinski, MA | 1 |
| Hirota, K; Sajiki, H; Sako, M; Sawada, M | 1 |
| Biasoli, G; Borgia, AL; Botta, M; Cappello, V; Ciomei, M; Corelli, F; Manetti, F; Mongelli, N | 1 |
| App, H; Fong, TA; Hirth, KP; Kim, YH; McMahon, G; Powell, TJ; Risau, W; Schreck, R; Shawver, LK; Sun, L; Tang, C; Ullrich, A; Wang, X | 1 |
| Bucana, CD; Davis, DW; Ellis, LM; Liu, W; McConkey, DJ; McMahon, G; Shaheen, RM; Wilson, MR; Zebrowski, BK | 1 |
| Angelov, L; Guha, A; McMahon, G; Roncari, L; Salhia, B | 1 |
| Camp, JP; Collier, JH; Hudson, TW; Schmidt, CE | 1 |
| Ellis, LM; Liu, W; Shaheen, RM; Takahashi, Y | 1 |
| Hirth, KP; Menger, MD; Schilling, L; Schmiedek, P; Thurnher, A; Ullrich, A; Vajkoczy, P | 1 |
| Arastéh, K; Hannah, A | 1 |
| Harris, AL | 1 |
| Fong, TA; Ge, S; Goldbrunner, R; Hirth, KP; Menger, MD; Rempel, SA; Schilling, L; Schmiedek, P; Tonn, JC; Ullrich, A; Vajkoczy, P; Vollmar, B | 1 |
| Fong, TA; Hirth, KP; Menger, MD; Schilling, L; Schmiedek, P; Ullrich, A; Vajkoczy, P; Vollmar, B | 1 |
| Blake, RA; Fong, TA; Hawtin, R; Hirth, KP; Hubbard, SR; Laird, AD; Liang, C; McMahon, G; Mohammadi, M; Schlessinger, J; Shawver, LK; Shenoy, N; Strawn, LM; Sun, L; Tang, C; Tang, F; Thurnher, A; Ullrich, A; Vajkoczy, P | 1 |
| Cherrington, JM; Li, G; Mendel, DB; Schreck, RE; Shawver, LK; Strawn, LM; Tanciongco, SS; Vasile, S; West, DC | 1 |
| Bucana, CD; Davis, DW; Drazan, KE; Ellis, LM; Liu, W; McConkey, DJ; McMahon, G; Ogura, Y; Reinmuth, N; Shaheen, RM; Tseng, WW; Vellagas, R; Wieczorek, AA | 1 |
| Donnelly, E; Geng, L; Hallahan, DE; Lin, PC; McMahon, G; Oshinka, H; Sierra-Rivera, E | 1 |
| Bucana, CD; Ellis, LM; Gallick, GE; Jung, YD; McConkey, DJ; McMahon, G; Solorzano, CC | 1 |
| Giles, FJ | 1 |
| Cooke, JP; Glassford, AJ; Heeschen, C; Weis, M | 1 |
| Baker, CH; Fidler, IJ; Solorzano, CC | 1 |
| Haspel, HC; McMahon, G; Scicli, AG; Scicli, GM | 1 |
| Bäckman, U; Christofferson, R; Jonsson, E; Larsson, R; Svensson, A | 1 |
76 review(s) available for pyrroles and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Evolving Treatment Paradigm in Metastatic Renal Cell Carcinoma.
Topics: Carcinoma, Renal Cell; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; Indoles; Neoplasm Metastasis; Neoplasm Proteins; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Quinolines; Sorafenib; Sunitinib; Von Hippel-Lindau Tumor Suppressor Protein | 2017 |
Angiogenesis Inhibitors in NSCLC.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Disease-Free Survival; Docetaxel; Humans; Indoles; Lung Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperidines; Pyrroles; Quinazolines; Ramucirumab; Sorafenib; Sunitinib; Taxoids | 2017 |
Sunitinib malate for the treatment of pancreas malignancies--where does it fit?
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Indoles; Neovascularization, Pathologic; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sunitinib | 2013 |
Pharmacokinetics and pharmacodynamics of sunitinib for the treatment of advanced pancreatic neuroendocrine tumors.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Clinical Trials, Phase III as Topic; Disease-Free Survival; Humans; Indoles; Neovascularization, Pathologic; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sunitinib | 2013 |
Current understanding of the molecular biology of pancreatic neuroendocrine tumors.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Cell Hypoxia; Co-Repressor Proteins; Cyclin-Dependent Kinase Inhibitor p18; Disease Progression; Disease-Free Survival; Everolimus; Gene Knock-In Techniques; Gene Knockout Techniques; Genetic Predisposition to Disease; Humans; Indoles; Islets of Langerhans; Molecular Chaperones; Molecular Targeted Therapy; Mutation; Neovascularization, Pathologic; Neuroendocrine Tumors; Nuclear Proteins; Octreotide; Pancreatic Neoplasms; Proto-Oncogene Proteins; Pyrroles; Receptor, Notch1; Signal Transduction; Sirolimus; Sunitinib; TOR Serine-Threonine Kinases | 2013 |
Sunitinib malate in the treatment of urothelial cancer.
Topics: Angiogenesis Inhibitors; Animals; Humans; Indoles; Neovascularization, Pathologic; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Urogenital Neoplasms | 2014 |
Tumor angiogenesis and anti-angiogenic therapies.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Gene Expression Regulation, Neoplastic; Humans; Indoles; Neoplasms; Neovascularization, Pathologic; Placenta Growth Factor; Pregnancy Proteins; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sunitinib; Vascular Endothelial Growth Factors | 2013 |
Resistance to sunitinib in renal cell carcinoma: From molecular mechanisms to predictive markers and future perspectives.
Topics: Angiogenesis Inhibitors; Biomarkers, Tumor; Carcinoma, Renal Cell; Drug Resistance, Neoplasm; Humans; Indoles; Kidney Neoplasms; Neovascularization, Pathologic; Prognosis; Pyrroles; Signal Transduction; Sunitinib; Tumor Microenvironment | 2015 |
Diagnostic and therapeutic implications of the vascular endothelial growth factor family in cancer.
Topics: Angiogenesis Inhibitors; Bevacizumab; Humans; Indoles; Neoplasm Metastasis; Neoplasm Staging; Neoplasms; Neovascularization, Pathologic; Prognosis; Protein Kinase Inhibitors; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factors | 2015 |
Combining radiotherapy with sunitinib: lessons (to be) learned.
Topics: Animals; Chemoradiotherapy; Humans; Indoles; Neoplasms; Neovascularization, Pathologic; Pyrroles; Sunitinib | 2015 |
[Tyrosine kinase inhibiting the VEGF pathway and elderly people: Tolerance, pre-treatment assessment and side effects management].
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Axitinib; Fatigue; Humans; Imidazoles; Indazoles; Indoles; Kidney; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib | 2016 |
Antiangiogenic Therapy in Pancreatic Neuroendocrine Tumors.
Topics: Angiogenesis Inhibitors; Animals; Bevacizumab; Humans; Indoles; Neovascularization, Pathologic; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sunitinib | 2016 |
Exploring the Benefit/Risk Associated with Antiangiogenic Agents for the Treatment of Non-Small Cell Lung Cancer Patients.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Humans; Indoles; Neovascularization, Pathologic; Pyrroles; Ramucirumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Risk Assessment; Sunitinib; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2017 |
Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations?
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Biomarkers, Tumor; Clinical Trials as Topic; Humans; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2008 |
Hypoxia-inducible factor in cancer angiogenesis: structure, regulation and clinical perspectives.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Cell Hypoxia; Enzyme Inhibitors; Humans; Hypoxia-Inducible Factor 1; Indoles; Intercellular Signaling Peptides and Proteins; Mustard Compounds; Neoplasms; Neovascularization, Pathologic; Phenylpropionates; Pyrroles; Sunitinib | 2009 |
[Potential role of antiangiogenic treatment in neuroblastoma].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Child; Clinical Trials as Topic; Humans; Indoles; Neovascularization, Pathologic; Neuroblastoma; Pyrroles; Sunitinib; United States; United States Food and Drug Administration | 2009 |
[Pharmacology profile of sunitinib malate (Sutent) Capsules) and clinical findings on this drug].
Topics: Animals; Antineoplastic Agents; Capsules; Carcinoma, Renal Cell; Clinical Trials as Topic; Gastrointestinal Stromal Tumors; Humans; Indoles; Kidney Neoplasms; Neovascularization, Pathologic; Pyrroles; Receptor, Platelet-Derived Growth Factor beta; Sunitinib; Vascular Endothelial Growth Factor Receptor-2 | 2009 |
Cardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitors.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Drug Administration Routes; Female; Hemorrhage; Humans; Hypertension; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Signal Transduction; Sorafenib; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2009 |
Renal toxicity of targeted therapies.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Hypertension; Indoles; Kidney; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proteinuria; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2009 |
Angiogenesis regulated by VEGF and its receptors and its clinical application.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Drug Design; Humans; Indoles; Neoplasms; Neoplastic Cells, Circulating; Neovascularization, Pathologic; Neovascularization, Physiologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Signal Transduction; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2009 |
The role of antiangiogenesis therapy: bevacizumab and beyond.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Clinical Trials as Topic; Combined Modality Therapy; Drug Delivery Systems; Forecasting; Humans; Indoles; Neoadjuvant Therapy; Neoplasm Proteins; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2009 |
Progress in the management of advanced renal cell carcinoma (RCC).
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Cell Transformation, Neoplastic; Everolimus; Humans; Indoles; Kidney Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Von Hippel-Lindau Tumor Suppressor Protein | 2010 |
Understanding the molecular-based mechanism of action of the tyrosine kinase inhibitor: sunitinib.
Topics: Angiogenesis Inhibitors; Breast Neoplasms; Carcinoma, Renal Cell; Colonic Neoplasms; Drug Resistance, Neoplasm; Female; Gastrointestinal Stromal Tumors; Humans; Indoles; Lung Neoplasms; Neovascularization, Pathologic; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Sunitinib | 2010 |
Targeting immune suppressing myeloid-derived suppressor cells in oncology.
Topics: Animals; Antineoplastic Agents; CD11b Antigen; Humans; Immune Tolerance; Immunotherapy; Indoles; Myeloid Cells; Neoplasms; Neovascularization, Pathologic; Proto-Oncogene Proteins c-kit; Pyrroles; Sunitinib; Tumor Microenvironment; Vascular Endothelial Growth Factor A | 2011 |
[Angiogenesis inhibition: review of the activity of sorafenib, sunitinib and bevacizumab].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2010 |
[Antiangionic drugs in soft tissue sarcoma].
Topics: Angiogenesis Inhibitors; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Doxorubicin; Humans; Indazoles; Indoles; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sarcoma; Soft Tissue Neoplasms; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A | 2010 |
Angiogenesis as a therapeutic target in urothelial carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Humans; Indoles; Matrix Metalloproteinases; Neoadjuvant Therapy; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Rats; Sorafenib; Sunitinib; Survival Rate; Treatment Outcome; Urinary Bladder; Urinary Bladder Neoplasms; Urothelium; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Xenograft Model Antitumor Assays | 2010 |
Antiangiogenic therapy for breast cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Breast Neoplasms; Female; Humans; Indoles; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2010 |
In pursuit of new anti-angiogenic therapies for cancer treatment.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Drug Resistance, Neoplasm; Humans; Indazoles; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Oligonucleotides; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Sorafenib; Sulfonamides; Sunitinib; Tumor Microenvironment | 2011 |
Therapeutic advances in women's cancers.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Cetuximab; ErbB Receptors; Female; Genital Neoplasms, Female; Humans; Indoles; Intestinal Perforation; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Poly(ADP-ribose) Polymerase Inhibitors; Protein-Tyrosine Kinases; PTEN Phosphohydrolase; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2011 |
[Novelties in the treatment for advanced renal-cell cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Everolimus; Humans; Indazoles; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2011 |
Targeting angiogenesis in esophagogastric adenocarcinoma.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Biomarkers, Tumor; Clinical Trials, Phase III as Topic; Disease Models, Animal; Disease-Free Survival; Esophageal Neoplasms; Gene Expression Regulation, Neoplastic; Humans; Indoles; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Polymorphism, Genetic; Protein Kinase Inhibitors; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2011 |
Angiogenesis in peritoneal dialysis.
Topics: Angiogenesis Inhibitors; Animals; Humans; Indoles; Neovascularization, Pathologic; Peritoneal Dialysis; Peritoneum; Pyrroles; Rats; Sunitinib | 2011 |
Biomarkers to predict response to sunitinib therapy and prognosis in metastatic renal cell cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Biomarkers; Biotransformation; Carcinoma, Renal Cell; Cell Hypoxia; Clinical Trials as Topic; Drug Monitoring; Drug Resistance, Neoplasm; Humans; Indoles; Kidney Neoplasms; Membrane Proteins; Multicenter Studies as Topic; Neoplasm Proteins; Neovascularization, Pathologic; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrroles; Receptors, Growth Factor; Retrospective Studies; Risk Factors; Severity of Illness Index; Sunitinib; Vascular Endothelial Growth Factor A | 2011 |
Role of biological targeted therapies in gastroenteropancreatic neuroendocrine tumours.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Endocrine Gland Neoplasms; Everolimus; Gastrointestinal Neoplasms; Humans; Indoles; Molecular Targeted Therapy; Neovascularization, Pathologic; Neuroendocrine Tumors; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyrroles; Sirolimus; Sunitinib; TOR Serine-Threonine Kinases | 2011 |
Emerging therapies targeting tumor vasculature in multiple myeloma and other hematologic and solid malignancies.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Benzenesulfonates; Hematologic Neoplasms; Humans; Indoles; Multiple Myeloma; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sunitinib; Thalidomide; Vascular Endothelial Growth Factor A; Wnt Signaling Pathway | 2011 |
Clinical experience with antiangiogenic therapy in leukemia.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Clinical Trials as Topic; Humans; Indoles; Lenalidomide; Leukemia; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Sorafenib; Staurosporine; Sunitinib; Thalidomide; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2011 |
Tyrosine kinase inhibitors for metastatic renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Costs; Humans; Indazoles; Indoles; Kidney Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Practice Guidelines as Topic; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A | 2011 |
Anti-angiogenic therapy: concept to clinic.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Biomarkers, Tumor; Humans; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2012 |
[Possibilities for inhibiting tumor-induced angiogenesis: results with multi-target tyrosine kinase inhibitors].
Topics: Angiogenesis Inhibitors; Animals; Axitinib; Benzenesulfonates; Humans; Imidazoles; Indazoles; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptors, Fibroblast Growth Factor; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sulfonamides; Sunitinib | 2012 |
New targeted agents in gastroenteropancreatic neuroendocrine tumors.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; Clinical Trials as Topic; Everolimus; Gastrointestinal Neoplasms; Humans; Indoles; Molecular Targeted Therapy; Neovascularization, Pathologic; Pancreatic Neoplasms; Pyrroles; Randomized Controlled Trials as Topic; Sirolimus; Sunitinib; TOR Serine-Threonine Kinases | 2012 |
Tyrosine kinase inhibitor-induced thyroid disorders: a review and hypothesis.
Topics: Humans; Hypothyroidism; Indoles; Neovascularization, Pathologic; Protein Kinase Inhibitors; Pyrroles; Receptor Protein-Tyrosine Kinases; Receptors, Platelet-Derived Growth Factor; Sunitinib; Thyroid Diseases; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2013 |
Targeting vascular endothelial growth factor in colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Disease-Free Survival; Endothelial Growth Factors; Female; Fluorouracil; Humans; Indoles; Irinotecan; Leucovorin; Male; Neovascularization, Pathologic; Prognosis; Pyrroles; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2002 |
Inhibitors of the vascular endothelial growth factor receptor.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Clinical Trials as Topic; Colorectal Neoplasms; Drug Design; Drug Screening Assays, Antitumor; Endothelial Growth Factors; Enzyme Inhibitors; Humans; Indoles; Intercellular Signaling Peptides and Proteins; Lymphokines; Neoplasm Proteins; Neoplasms; Neovascularization, Pathologic; Phthalazines; Piperidines; Pyridines; Pyrroles; Quinazolines; Recombinant Proteins; RNA, Catalytic; Treatment Failure; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factors | 2002 |
A targeted approach for antiangiogenic therapy of metastatic human colon cancer.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Colonic Neoplasms; Colorectal Neoplasms; Endothelial Growth Factors; Extracellular Matrix; Humans; Indoles; Integrins; Intercellular Signaling Peptides and Proteins; Lymphokines; Neovascularization, Pathologic; Oxindoles; Propionates; Pyrroles; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2003 |
[Clinical development of anti-angiogenic agents in 2002].
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Clinical Trials, Phase I as Topic; Collagen; Endostatins; Endothelial Growth Factors; Humans; Indoles; Intercellular Signaling Peptides and Proteins; Lymphokines; Neovascularization, Pathologic; Peptide Fragments; Pyrroles; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2003 |
Anti-vascular tumor therapy: recent advances, pitfalls and clinical perspectives.
Topics: Animals; Anti-HIV Agents; Drug Delivery Systems; Humans; Indoles; Neoplasms; Neovascularization, Pathologic; Protein Kinase Inhibitors; Pyrroles; Randomized Controlled Trials as Topic; Sunitinib | 2004 |
Vascular endothelial growth factor in esophageal cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Barrett Esophagus; Bevacizumab; Carcinoma, Squamous Cell; Esophageal Neoplasms; Humans; Indoles; Lymphangiogenesis; Neovascularization, Pathologic; Oxindoles; Prognosis; Propionates; Protein-Tyrosine Kinases; Pyrroles; RNA, Catalytic; RNA, Messenger; Vascular Endothelial Growth Factor A | 2004 |
Early clinical data with small-molecule vascular endothelial growth factor tyrosine kinase receptor inhibitors.
Topics: Angiogenesis Inhibitors; Clinical Trials, Phase I as Topic; Female; Humans; Indoles; Lung Neoplasms; Male; Neoplasm Invasiveness; Neovascularization, Pathologic; Phthalazines; Prognosis; Pyridines; Pyrroles; Receptor Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Risk Assessment; Sunitinib; Treatment Outcome | 2004 |
Targeting angiogenesis with vascular endothelial growth factor receptor small-molecule inhibitors: novel agents with potential in lung cancer.
Topics: Benzenesulfonates; Clinical Trials as Topic; Humans; Indoles; Lung Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2005 |
Anti-angiogenic and anti-HER therapy.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Clinical Trials as Topic; ErbB Receptors; Humans; Indoles; Neoplasms; Neovascularization, Pathologic; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor | 2006 |
Sunitinib: a newly approved small-molecule inhibitor of angiogenesis.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Drug Approval; Humans; In Vitro Techniques; Indoles; Neoplasms; Neovascularization, Pathologic; Pyrroles; Sunitinib; United States; United States Food and Drug Administration | 2006 |
The role of angiogenesis inhibition in the treatment of breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Indoles; Multicenter Studies as Topic; Neoplasm Metastasis; Neovascularization, Pathologic; Paclitaxel; Pyrroles; Randomized Controlled Trials as Topic; Sunitinib; Survival Rate; Vascular Endothelial Growth Factor A | 2006 |
Molecularly targeted therapy in renal cell carcinoma: where do we go from here?
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Case Management; Clinical Trials as Topic; Combined Modality Therapy; Cytokines; Humans; Indoles; Kidney Neoplasms; Neovascularization, Pathologic; Nephrectomy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2006 |
Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Indoles; Kidney Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2007 |
PDGF receptors as targets in tumor treatment.
Topics: Animals; Antineoplastic Agents; Benzamides; Clinical Trials, Phase III as Topic; Drug Delivery Systems; Extracellular Fluid; Fibroblasts; Humans; Imatinib Mesylate; Indoles; Mutation; Neoplasm Metastasis; Neoplasm Proteins; Neoplasms; Neovascularization, Pathologic; Piperazines; Platelet-Derived Growth Factor; Pressure; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptors, Platelet-Derived Growth Factor; Signal Transduction; Sunitinib; Translocation, Genetic | 2007 |
Angiogenesis in cancer: molecular mechanisms, clinical impact.
Topics: Angiogenesis Inhibitors; Angiogenic Proteins; Benzenesulfonates; Carcinoma, Squamous Cell; Humans; Indoles; Microcirculation; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2007 |
[Clinical importance of angiogenesis and angiogenic factors in oncohematology].
Topics: Angiogenesis Inducing Agents; Angiogenesis Inhibitors; Angiopoietin-1; Angiopoietin-2; Hematologic Neoplasms; Humans; Indoles; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasm Metastasis; Neovascularization, Pathologic; Oxindoles; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Propionates; Pyrroles; Receptor, TIE-2; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factors | 2007 |
Sunitinib (Sutent): a novel agent for the treatment of metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Cell Proliferation; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Neovascularization, Pathologic; Pyrroles; Sunitinib | 2007 |
Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Enzyme Inhibitors; Humans; Indoles; Lung Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperidines; Pyridines; Pyrroles; Quinazolines; Signal Transduction; Sorafenib; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-1 | 2007 |
[Effect of angiogenesis inhibitors on renal cell carcinoma].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinases; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sunitinib; Survival Analysis; TOR Serine-Threonine Kinases; Treatment Outcome; Vascular Endothelial Growth Factor A | 2007 |
Angiogenesis as targeted breast cancer therapy.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Breast Neoplasms; Female; Humans; Indoles; Neoplasm Metastasis; Neovascularization, Pathologic; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor A | 2007 |
Surrogate biomarkers in evaluating response to anti-angiogenic agents: focus on sunitinib.
Topics: Angiogenesis Inhibitors; Biomarkers, Tumor; Endothelial Cells; Humans; Indoles; Neoplasms; Neovascularization, Pathologic; Pyrroles; Sunitinib | 2007 |
A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Humans; Indoles; Neoplasms; Neovascularization, Pathologic; Protein Kinase Inhibitors; Pyrroles; Receptor Protein-Tyrosine Kinases; Sunitinib | 2007 |
[Oral drugs inhibiting the VEGF pathway].
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Asthenia; Axitinib; Benzenesulfonates; Humans; Hypertension; Imidazoles; Indazoles; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Piperidines; Proteinuria; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2007 |
[Angiogenesis and renal cell carcinoma].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Drug Resistance, Neoplasm; Humans; Hypertension; Indoles; Kidney Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Proteinuria; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Sorafenib; Sunitinib; Vascular Endothelial Growth Factors | 2007 |
Sunitinib.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Humans; Indoles; Neoplasms; Neovascularization, Pathologic; Pyrroles; Sunitinib | 2007 |
Playing only one instrument may be not enough: limitations and future of the antiangiogenic treatment of cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Indoles; Lung Neoplasms; Models, Biological; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2007 |
[Angiogenesis targeting in renal carcinomas].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sunitinib | 2007 |
[Renal cell carcinoma and antiangiogenic therapies].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Humans; Indoles; Kidney Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2008 |
Carboxyethylpyrrole adducts, age-related macular degeneration and neovascularization.
Topics: Aged, 80 and over; Aging; Allantois; Animals; Chick Embryo; Child; Humans; Macular Degeneration; Mice; Middle Aged; Models, Biological; Molecular Structure; Neovascularization, Pathologic; Pyrroles | 2008 |
From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzenesulfonates; Bevacizumab; Cetuximab; Clinical Trials as Topic; Enzyme Inhibitors; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Indoles; Lapatinib; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperazines; Piperidines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Sorafenib; Sunitinib; Trastuzumab | 2008 |
Vascular endothelial growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: a review of recent clinical trials.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Humans; Indoles; Neovascularization, Pathologic; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperidines; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Treatment Outcome | 2007 |
The role of vascular endothelial growth factor (VEGF) in AIDS-related Kaposi's sarcoma.
Topics: AIDS-Related Opportunistic Infections; Angiogenesis Inhibitors; Antiviral Agents; Endothelial Growth Factors; Enzyme Inhibitors; HIV-1; Humans; Indoles; Lymphokines; Neovascularization, Pathologic; Protein Isoforms; Protein-Tyrosine Kinases; Pyrroles; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Receptors, Mitogen; Receptors, Vascular Endothelial Growth Factor; Sarcoma, Kaposi; Skin Neoplasms; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2000 |
von Hippel-Lindau syndrome: target for anti-vascular endothelial growth factor (VEGF) receptor therapy.
Topics: Angiogenesis Inhibitors; Endothelial Growth Factors; Enzyme Inhibitors; Genes, Tumor Suppressor; Germ-Line Mutation; Humans; Indoles; Lymphokines; Neovascularization, Pathologic; Protein Isoforms; Protein-Tyrosine Kinases; Pyrroles; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Receptors, Mitogen; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; von Hippel-Lindau Disease | 2000 |
The vascular endothelial growth factor (VEGF) signaling pathway: a therapeutic target in patients with hematologic malignancies.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Disease Progression; Endothelial Growth Factors; Enzyme Inhibitors; Hematologic Neoplasms; Humans; Indoles; Lymphokines; Matrix Metalloproteinases; Neovascularization, Pathologic; Protein-Tyrosine Kinases; Pyrroles; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2001 |
16 trial(s) available for pyrroles and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Magnetic resonance imaging biomarkers in hepatocellular carcinoma: association with response and circulating biomarkers after sunitinib therapy.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Diffusion Magnetic Resonance Imaging; Disease-Free Survival; Female; Humans; Indoles; Liver Neoplasms; Male; Middle Aged; Neovascularization, Pathologic; Pyrroles; Sunitinib | 2013 |
Serum C-Telopeptide Collagen Crosslinks and Plasma Soluble VEGFR2 as Pharmacodynamic Biomarkers in a Trial of Sequentially Administered Sunitinib and Cilengitide.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Biomarkers, Tumor; Collagen Type I; Female; Humans; Indoles; Male; Middle Aged; Neoplasm Staging; Neoplasms; Neovascularization, Pathologic; Peptides; Pyrroles; Snake Venoms; Sunitinib; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
Biomarker Analysis in a Phase II Study of Sunitinib in Patients with Advanced Melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Endothelial Cells; Endpoint Determination; Female; Humans; Indoles; Male; Melanoma; Middle Aged; Mutation; Neovascularization, Pathologic; Placenta Growth Factor; Pregnancy Proteins; Proto-Oncogene Proteins c-kit; Pyrroles; Skin Neoplasms; Sunitinib; Survival Analysis; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
Impact of Acquisition Method and Region of Interest Placement on Inter-observer Agreement and Measurement of Tumor Response to Targeted Therapy Using Dynamic Contrast-Enhanced Ultrasound.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Contrast Media; Disease-Free Survival; Drug Monitoring; Female; Humans; Image Interpretation, Computer-Assisted; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neovascularization, Pathologic; Observer Variation; Patient Positioning; Pyrroles; Reproducibility of Results; Sensitivity and Specificity; Sunitinib; Treatment Outcome; Ultrasonography | 2016 |
A Phase I Clinical, Pharmacokinetic, and Pharmacodynamic Study of Weekly or Every Three Week Ixabepilone and Daily Sunitinib in Patients with Advanced Solid Tumors.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Drug Administration Schedule; Epothilones; Female; Humans; Indoles; Male; Middle Aged; Neoplasms; Neovascularization, Pathologic; Pyrroles; Sunitinib; Tubulin Modulators | 2016 |
Bridging Sunitinib Exposure to Time-to-Tumor Progression in Hepatocellular Carcinoma Patients With Mathematical Modeling of an Angiogenic Biomarker.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease Progression; Humans; Indoles; Liver Neoplasms; Models, Theoretical; Neovascularization, Pathologic; Pilot Projects; Pyrroles; Sunitinib; Survival Rate; Time Factors; Vascular Endothelial Growth Factor Receptor-2 | 2016 |
Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Biomarkers, Tumor; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neovascularization, Pathologic; Platelet-Derived Growth Factor; Prognosis; Pyrroles; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2009 |
Phase II trial of sunitinib maintenance therapy after platinum-based chemotherapy in patients with extensive-stage small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Early Termination of Clinical Trials; Etoposide; Female; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neovascularization, Pathologic; Patient Dropouts; Platinum; Pyrroles; Small Cell Lung Carcinoma; Sunitinib; Treatment Outcome | 2011 |
A multicenter phase II study of TSU-68, a novel oral multiple tyrosine kinase inhibitor, in patients with metastatic breast cancer progressing despite prior treatment with an anthracycline-containing regimen and taxane.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Bridged-Ring Compounds; Drug Administration Schedule; Female; Gene Expression Regulation, Neoplastic; Humans; Indoles; Middle Aged; Neovascularization, Pathologic; Oxindoles; Propionates; Protein Kinase Inhibitors; Pyrroles; Taxoids; Treatment Outcome; Vascular Endothelial Growth Factor A | 2013 |
Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure.
Topics: Adult; Aged; Benzamides; Biomarkers, Tumor; Cross-Over Studies; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Neovascularization, Pathologic; Piperazines; Placebos; Pyrimidines; Pyrroles; Retreatment; Sunitinib; Survival Analysis; Young Adult | 2012 |
Analysis of coagulation cascade and endothelial cell activation during inhibition of vascular endothelial growth factor/vascular endothelial growth factor receptor pathway in cancer patients.
Topics: Angiogenesis Inhibitors; Blood Coagulation; Blood Platelets; Carcinoma, Renal Cell; Cell Division; Cell Membrane Permeability; Cell Movement; Drug Administration Schedule; Endothelium, Vascular; Fibrinolysis; Hemostasis; Humans; Indoles; Kidney Neoplasms; Melanoma; Neovascularization, Pathologic; Protein C; Proto-Oncogene Proteins; Pyrroles; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor; Sarcoma; Thrombin; Vascular Endothelial Growth Factor Receptor-1 | 2002 |
Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Disease-Free Survival; Enzyme Inhibitors; Female; Humans; Indoles; Kidney Neoplasms; Male; Melanoma; Middle Aged; Neovascularization, Pathologic; Protein-Tyrosine Kinases; Pyrroles; Sarcoma; Skin Neoplasms; Treatment Outcome | 2003 |
SU5416 plus interferon alpha in advanced renal cell carcinoma: a phase II California Cancer Consortium Study with biological and imaging correlates of angiogenesis inhibition.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; California; Carcinoma, Renal Cell; Cell Line, Tumor; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Immunotherapy; Indoles; Interferon alpha-2; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Neovascularization, Pathologic; Pyrroles; Recombinant Proteins; Time Factors; Tomography, Emission-Computed; Treatment Outcome; Vascular Endothelial Growth Factor A | 2003 |
Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Biomarkers, Tumor; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Indoles; Male; Middle Aged; Multiple Myeloma; Neovascularization, Pathologic; Protein-Tyrosine Kinases; Pyrroles; Remission Induction; Salvage Therapy; Survival Rate; Thalidomide; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2004 |
Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in advanced melanoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Female; Glucose; Humans; Indoles; Lymphocytes; Magnetic Resonance Imaging; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Neovascularization, Pathologic; Protein Kinase Inhibitors; Pyrroles; Time Factors; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2004 |
Inflammatory breast cancer as a model disease to study tumor angiogenesis: results of a phase IB trial of combination SU5416 and doxorubicin.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Doxorubicin; Female; Humans; Indoles; Inflammation; Male; Maximum Tolerated Dose; Middle Aged; Neovascularization, Pathologic; Pyrroles; Treatment Outcome | 2007 |
259 other study(ies) available for pyrroles and Angiogenesis, Pathologic
| Article | Year |
|---|---|
10Z‑Hymenialdisine inhibits angiogenesis by suppressing NF‑κB activation in pancreatic cancer cell lines.
Topics: Angiogenesis Inhibitors; Animals; Azepines; Cell Line, Tumor; Disease Models, Animal; Humans; Mice; Neovascularization, Pathologic; NF-kappa B; Pancreatic Neoplasms; Pyrroles | 2022 |
Epigallocatechin-3-gallate inhibits tumor angiogenesis: involvement of endoglin/Smad1 signaling in human umbilical vein endothelium cells.
Topics: Angiogenesis Inhibitors; Catechin; Cell Movement; Cell Proliferation; Cells, Cultured; Endoglin; Human Umbilical Vein Endothelial Cells; Humans; Indoles; Neoplasm Invasiveness; Neovascularization, Pathologic; Pyrroles; Signal Transduction; Smad1 Protein; Vascular Endothelial Growth Factor A | 2019 |
Therapeutic effects of blocking β-catenin against hepatocellular carcinoma-induced activation of inflammation, fibrosis and tumor invasion.
Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; beta Catenin; Cell Movement; Cytokines; Fibroblast Growth Factor 2; Fibrosis; Inflammation Mediators; Liver Neoplasms, Experimental; Male; Matrix Metalloproteinase 9; Neoplasm Invasiveness; Neovascularization, Pathologic; Pyridines; Pyrroles; Rats, Sprague-Dawley; Thiazolidinediones; Thioacetamide; Transforming Growth Factor beta1; Wnt Signaling Pathway | 2021 |
Synthesis and Evaluation of Novel 2-Pyrrolidone-Fused (2-Oxoindolin-3-ylidene)methylpyrrole Derivatives as Potential Multi-Target Tyrosine Kinase Receptor Inhibitors.
Topics: Angiogenesis Inhibitors; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Gene Expression; HCT116 Cells; Humans; Indoles; Molecular Docking Simulation; Neovascularization, Pathologic; Protein Kinase Inhibitors; Protein Structure, Secondary; Pyrroles; Pyrrolidinones; Receptor, Platelet-Derived Growth Factor beta; Sunitinib; Vascular Endothelial Growth Factor Receptor-2 | 2017 |
Antiangiogenic agents targeting different angiogenic pathways have opposite effects on tumor hypoxia in R-18 human melanoma xenografts.
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Female; Humans; Indoles; Melanoma; Mice; Neovascularization, Pathologic; Peptide Fragments; Properdin; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sunitinib; Tumor Hypoxia; Xenograft Model Antitumor Assays | 2017 |
Kinase inhibitors of the IGF-1R as a potential therapeutic agent for rheumatoid arthritis.
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Cell Line; Cell Proliferation; Female; Humans; Insulin-Like Growth Factor I; Macrophage Colony-Stimulating Factor; Mice; Neovascularization, Pathologic; Osteoclasts; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; RANK Ligand; Receptor, IGF Type 1; Receptors, Somatomedin; Signal Transduction | 2017 |
A pyrrole-based natural small molecule mitigates HSP90 expression in MDA-MB-231 cells and inhibits tumor angiogenesis in mice by inactivating HSF-1.
Topics: Animals; Cell Line, Tumor; Cell Movement; Cornea; Down-Regulation; Female; Heat Shock Transcription Factors; HSP70 Heat-Shock Proteins; HSP90 Heat-Shock Proteins; Humans; Mice; Mitogen-Activated Protein Kinase 3; Neoplasms; Neovascularization, Pathologic; Phosphatidylinositol 3-Kinases; Phosphorylation; Plant Leaves; Proto-Oncogene Proteins c-akt; Pyrroles; Rats; Rats, Wistar; Tinospora; Transplantation, Heterologous | 2017 |
Autophagy Inhibition Improves Sunitinib Efficacy in Pancreatic Neuroendocrine Tumors via a Lysosome-dependent Mechanism.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Autophagy; Cell Line, Tumor; Cell Membrane Permeability; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Gene Knockdown Techniques; Humans; Indoles; Lysosomal-Associated Membrane Protein 2; Lysosomes; Mice; Neovascularization, Pathologic; Neuroendocrine Tumors; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyrroles; Sunitinib | 2017 |
Combination therapy using molecular-targeted drugs modulates tumor microenvironment and impairs tumor growth in renal cell carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Drug Therapy, Combination; Everolimus; Female; Humans; Immunohistochemistry; Indoles; Kidney Neoplasms; Luminescent Measurements; Mice; Molecular Imaging; Molecular Targeted Therapy; Neovascularization, Pathologic; Platelet-Derived Growth Factor; Pyrroles; Signal Transduction; Stromal Cells; Sunitinib; TOR Serine-Threonine Kinases; Tumor Burden; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2017 |
Bortezomib Alone and in Combination With Salinosporamid A Induces Apoptosis and Promotes Pheochromocytoma Cell Death In Vitro and in Female Nude Mice.
Topics: Adrenal Gland Neoplasms; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bortezomib; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Female; Lactones; Mice; Mice, Nude; Neoplasm Invasiveness; Neovascularization, Pathologic; Pheochromocytoma; Proteasome Inhibitors; Pyrroles | 2017 |
EZH2 Modifies Sunitinib Resistance in Renal Cell Carcinoma by Kinome Reprogramming.
Topics: Animals; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Cell Line, Tumor; Drug Resistance, Neoplasm; Enhancer of Zeste Homolog 2 Protein; Female; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Mice; Mice, Inbred ICR; Mice, SCID; Neovascularization, Pathologic; Phosphorylation; Pyrroles; Receptor Protein-Tyrosine Kinases; Sunitinib; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2017 |
Pro-angiogenic gene expression is associated with better outcome on sunitinib in metastatic clear-cell renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neovascularization, Pathologic; Pyrroles; Sunitinib; Transcriptome; Treatment Outcome | 2018 |
Inhibition of JAK-STAT Signaling Suppresses Pathogenic Immune Responses in Medium and Large Vessel Vasculitis.
Topics: Adaptive Immunity; Adoptive Transfer; Aged; Animals; Cell Proliferation; Cytokines; Disease Models, Animal; Female; Gene Expression Regulation; Giant Cell Arteritis; Heterografts; Humans; Immunity, Innate; Immunologic Memory; Janus Kinase 1; Janus Kinase 3; Janus Kinase Inhibitors; Janus Kinases; Lymphocyte Activation; Male; Mice, Inbred NOD; Mice, SCID; Mice, Transgenic; Middle Aged; Neointima; Neovascularization, Pathologic; Piperidines; Pyrimidines; Pyrroles; Signal Transduction; STAT Transcription Factors; T-Lymphocytes; Temporal Arteries; Vascular Remodeling | 2018 |
Monocarboxylate transporters MCT1 and MCT4 are independent prognostic biomarkers for the survival of patients with clear cell renal cell carcinoma and those receiving therapy targeting angiogenesis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Renal Cell; Cohort Studies; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Monocarboxylic Acid Transporters; Muscle Proteins; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Prognosis; Pyrroles; Sorafenib; Sunitinib; Survival Rate; Symporters; Vascular Endothelial Growth Factor A | 2018 |
DCE-MRI of Sunitinib-Induced Changes in Tumor Microvasculature and Hypoxia: A Study of Pancreatic Ductal Adenocarcinoma Xenografts.
Topics: Animals; Biomarkers; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Contrast Media; Disease Models, Animal; Female; Humans; Hypoxia; Image Enhancement; Immunohistochemistry; Indoles; Magnetic Resonance Imaging; Male; Mice; Neovascularization, Pathologic; Pancreatic Neoplasms; Pyrroles; Sunitinib; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2018 |
Small Molecule Derived From Carboxyethylpyrrole Protein Adducts Promotes Angiogenesis in a Mouse Model of Peripheral Arterial Disease.
Topics: Animals; Cell Proliferation; Cells, Cultured; Disease Models, Animal; Endothelium, Vascular; Female; Hindlimb; Humans; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; Peripheral Arterial Disease; Pyrroles | 2018 |
In silico insights into the identification of potential novel angiogenic inhibitors against human VEGFR-2: a new SAR-based hierarchical clustering approach.
Topics: Algorithms; Angiogenesis Inhibitors; Computer Simulation; Humans; Ligands; Molecular Docking Simulation; Neovascularization, Pathologic; Protein Binding; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; User-Computer Interface; Vascular Endothelial Growth Factor Receptor-2 | 2018 |
The pyrrolopyrimidine colchicine-binding site agent PP-13 reduces the metastatic dissemination of invasive cancer cells in vitro and in vivo.
Topics: Animals; Antimitotic Agents; Antineoplastic Agents; Binding Sites; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chick Embryo; Colchicine; Female; Humans; Mice, Inbred Strains; Neovascularization, Pathologic; Pyrimidines; Pyrroles; Spheroids, Cellular; Xenograft Model Antitumor Assays | 2019 |
Inducing cancer indolence by targeting mitochondrial Complex I is potentiated by blocking macrophage-mediated adaptive responses.
Topics: Adenoma, Oxyphilic; Aminopyridines; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drosophila; Electron Transport Complex I; Female; Gene Knockout Techniques; HCT116 Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Macrophages; Metformin; Mice; Mice, Knockout; Mice, Nude; NADH Dehydrogenase; Neovascularization, Pathologic; Pyrroles; Xenograft Model Antitumor Assays | 2019 |
SU5416 does not attenuate early RV angiogenesis in the murine chronic hypoxia PH model.
Topics: Angiogenesis Inhibitors; Animals; Chronic Disease; Heart Ventricles; Hypertension, Pulmonary; Hypoxia; Indoles; Male; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; Pyrroles | 2019 |
Targeting renal cell carcinoma with gambogic acid in combination with sunitinib in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Down-Regulation; G1 Phase; Indoles; Kidney Neoplasms; Male; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; NF-kappa B; Pyrroles; Signal Transduction; Sunitinib; Up-Regulation; Xanthones; Xenograft Model Antitumor Assays | 2012 |
Antitumor efficacy of the heparanase inhibitor SST0001 alone and in combination with antiangiogenic agents in the treatment of human pediatric sarcoma models.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Cell Line, Tumor; Child; Drug Synergism; Female; Glucuronidase; Heparin; Humans; Indoles; Mice; Mice, Nude; Neoplasm Invasiveness; Neovascularization, Pathologic; Osteosarcoma; Pyrroles; Rhabdomyosarcoma; Sunitinib; Xenograft Model Antitumor Assays | 2013 |
Anti-angiogenic and anti-metastatic activity of synthetic phosphoethanolamine.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Renal Cell; Caspase 3; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cyclin D1; Cytoskeleton; Ethanolamines; Gene Expression Regulation, Neoplastic; Human Umbilical Vein Endothelial Cells; Humans; Indoles; Kidney Tubules, Proximal; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mitochondria; Neoplasm Metastasis; Neovascularization, Pathologic; Oxidation-Reduction; Pyrroles; Rats; Sunitinib; Transcription, Genetic; Vascular Endothelial Growth Factor Receptor-1; Wound Healing | 2013 |
Influence of soluble or matrix-bound isoforms of vascular endothelial growth factor-A on tumor response to vascular-targeted strategies.
Topics: Animals; Fibrosarcoma; Gene Expression Regulation, Neoplastic; Humans; Indoles; Mice; Neovascularization, Pathologic; Protein Isoforms; Pyrroles; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2013 |
Antiangiogenic therapy promoted metastasis of hepatocellular carcinoma by suppressing host-derived interleukin-12b in mouse models.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Dendritic Cells; Diphosphonates; Heterografts; Humans; Imidazoles; Immunosuppression Therapy; Indoles; Interleukin-12 Subunit p40; Killer Cells, Natural; Liver Neoplasms; Lung Neoplasms; Macrophages; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout; Mice, Nude; Neoplasm Transplantation; Neoplastic Cells, Circulating; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Zoledronic Acid | 2013 |
Loss of Pten promotes angiogenesis and enhanced vegfaa expression in zebrafish.
Topics: Animals; Chromones; Drug Therapy, Combination; Endothelial Cells; Haploinsufficiency; Hemangiosarcoma; Humans; Indoles; Morpholines; Mutation; Neovascularization, Pathologic; Phosphoprotein Phosphatases; Proto-Oncogene Proteins c-akt; Pseudopodia; Pyrroles; RNA, Messenger; Sunitinib; Up-Regulation; Vascular Endothelial Growth Factor A; Zebrafish; Zebrafish Proteins | 2013 |
Survey of activated kinase proteins reveals potential targets for cholangiocarcinoma treatment.
Topics: Angiogenesis Inhibitors; Apoptosis; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Blotting, Western; Cell Communication; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cholangiocarcinoma; Enzyme Activation; Humans; Indoles; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Kinases; Proto-Oncogene Proteins c-akt; Pyrroles; Signal Transduction; Sorafenib; Sunitinib | 2013 |
Dacarbazine in solitary fibrous tumor: a case series analysis and preclinical evidence vis-a-vis temozolomide and antiangiogenics.
Topics: Adult; Aged; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Dacarbazine; Female; Follow-Up Studies; Humans; Indazoles; Indoles; Male; Mice; Mice, SCID; Middle Aged; Neoplasm Staging; Neovascularization, Pathologic; Prognosis; Pyrimidines; Pyrroles; Retrospective Studies; Solitary Fibrous Tumors; Sulfonamides; Sunitinib; Temozolomide; Xenograft Model Antitumor Assays | 2013 |
Changes in tumour vessel density upon treatment with anti-angiogenic agents: relationship with response and resistance to therapy.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Biomarkers, Tumor; Blood Vessels; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neovascularization, Pathologic; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sulfonamides; Sunitinib | 2013 |
Vessel size imaging (VSI) by robust magnetic resonance (MR) relaxometry: MR-VSI of solid tumors in correlation with immunohistology and intravital microscopy.
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Dextrans; Female; Humans; Immunohistochemistry; Indoles; Magnetic Resonance Imaging; Magnetite Nanoparticles; Mice; Mice, Nude; Microscopy; Neoplasm Transplantation; Neoplasms, Experimental; Neovascularization, Pathologic; Pyrroles; Random Allocation; Sunitinib | 2013 |
EMMPRIN promotes angiogenesis, proliferation, invasion and resistance to sunitinib in renal cell carcinoma, and its level predicts patient outcome.
Topics: Adult; Aged; Aged, 80 and over; Animals; Apoptosis; Basigin; Blotting, Western; Carcinoma, Renal Cell; Cell Movement; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Female; Humans; Immunoenzyme Techniques; Indoles; Kidney; Kidney Neoplasms; Male; Mice; Mice, Inbred BALB C; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Neovascularization, Pathologic; Pyrroles; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Sunitinib; Tumor Cells, Cultured | 2013 |
Analyses of potential predictive markers and survival data for a response to sunitinib in patients with metastatic renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antigens, Neoplasm; Biomarkers, Tumor; Carbonic Anhydrase IX; Carbonic Anhydrases; Carcinoma, Renal Cell; DNA Mutational Analysis; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; Indoles; Ki-67 Antigen; Kidney Neoplasms; Neovascularization, Pathologic; Platelet Endothelial Cell Adhesion Molecule-1; Prognosis; Proportional Hazards Models; Pyrroles; Sunitinib; Time Factors; Tissue Array Analysis; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Von Hippel-Lindau Tumor Suppressor Protein | 2013 |
Interferon alpha and rapamycin inhibit the growth of pheochromocytoma PC12 line in vitro.
Topics: Adrenal Gland Neoplasms; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Cell Proliferation; Endostatins; Growth Hormone-Releasing Hormone; Indoles; Interferon-alpha; Neovascularization, Pathologic; PC12 Cells; Pheochromocytoma; Pyrroles; Rats; Sirolimus; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A | 2013 |
Tyrosine kinase inhibitor-induced vasculopathy in clear cell renal cell carcinoma: an unrecognized antitumour mechanism.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neovascularization, Pathologic; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sorafenib; Sunitinib | 2014 |
The effect of the anti-angiogenic drug sunitinib malate on the vascular architecture of oral squamous cell carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Blood Vessels; Carcinoma, Squamous Cell; Cricetinae; Humans; Indoles; Male; Mesocricetus; Microscopy, Electron, Scanning; Mouth Neoplasms; Neovascularization, Pathologic; Pyrroles; Sunitinib | 2014 |
Oncolytic vaccinia virus demonstrates antiangiogenic effects mediated by targeting of VEGF.
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Inhibitors; Genetic Therapy; Humans; Indoles; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Neovascularization, Pathologic; Oncolytic Virotherapy; Oncolytic Viruses; Protein-Tyrosine Kinases; Pyrroles; Sunitinib; Vaccinia virus; Vascular Endothelial Growth Factor A | 2014 |
Antiangiogenic therapy inhibits the recruitment of vascular accessory cells to the perivascular niche in glioma angiogenesis.
Topics: Angiogenesis Inhibitors; Animals; Biomarkers, Tumor; Bone Marrow Cells; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Glioma; Indoles; Mice; Mice, Nude; Neovascularization, Pathologic; Pyrroles; Rats; Sunitinib; Tumor Microenvironment | 2014 |
Longitudinal monitoring of tumor antiangiogenic therapy with near-infrared fluorophore-labeled agents targeted to integrin αvβ3 and vascular endothelial growth factor.
Topics: Animals; Colonic Neoplasms; Fluorescent Dyes; Glioblastoma; HT29 Cells; Humans; Indoles; Infrared Rays; Integrin alphaVbeta3; Longitudinal Studies; Mice; Molecular Targeted Therapy; Neovascularization, Pathologic; Optical Imaging; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor A | 2014 |
Comparison of dynamic contrast-enhanced MR, ultrasound and optical imaging modalities to evaluate the antiangiogenic effect of PF-03084014 and sunitinib.
Topics: Amyloid Precursor Protein Secretases; Angiogenesis Inhibitors; Cell Line, Tumor; Contrast Media; Humans; Indoles; Magnetic Resonance Imaging; Molecular Imaging; Neovascularization, Pathologic; Pyrroles; Radiography; Sunitinib; Tetrahydronaphthalenes; Ultrasonography; Valine; Xenograft Model Antitumor Assays | 2014 |
In vivo imaging of tumor physiological, metabolic, and redox changes in response to the anti-angiogenic agent sunitinib: longitudinal assessment to identify transient vascular renormalization.
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Contrast Media; Cyclic N-Oxides; Electron Spin Resonance Spectroscopy; Female; Humans; Indoles; Magnetic Resonance Imaging; Mice, Inbred C3H; Mice, Nude; Neoplasms; Neovascularization, Pathologic; Oxidation-Reduction; Oxygen; Pyrroles; Pyruvic Acid; Sunitinib; Xenograft Model Antitumor Assays | 2014 |
The relevance of testing the efficacy of anti-angiogenesis treatments on cells derived from primary tumors: a new method for the personalized treatment of renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Carcinoma, Renal Cell; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Gene Expression; Humans; Indoles; Kidney Neoplasms; Mice; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplasm Staging; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Precision Medicine; Pyrroles; Receptor Protein-Tyrosine Kinases; Sorafenib; Sunitinib; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2014 |
Metastatic hepatic epithelioid hemangio-endothelioma: long-term response to sunitinib malate.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Female; Hemangioendothelioma, Epithelioid; Humans; Indoles; Liver Neoplasms; Longitudinal Studies; Lung Neoplasms; Male; Neovascularization, Pathologic; Pyrroles; Sunitinib; Treatment Outcome | 2014 |
Chloroquine synergizes sunitinib cytotoxicity via modulating autophagic, apoptotic and angiogenic machineries.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Caco-2 Cells; Carcinoma, Ehrlich Tumor; Cell Line, Tumor; Cell Survival; Chloroquine; Drug Synergism; Female; HCT116 Cells; HeLa Cells; Hep G2 Cells; Humans; Immunohistochemistry; Indoles; MCF-7 Cells; Mice; Neovascularization, Pathologic; Pyrroles; Sunitinib | 2014 |
A method to assess target gene involvement in angiogenesis in vitro and in vivo using lentiviral vectors expressing shRNA.
Topics: Adipocytes; Animals; Cell Line, Tumor; Coculture Techniques; Endothelial Cells; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Genetic Vectors; Humans; Indoles; Lentivirus; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Pyrroles; RNA, Small Interfering; Sp1 Transcription Factor; Stem Cells; Sunitinib | 2014 |
Sunitinib suppress neuroblastoma growth through degradation of MYCN and inhibition of angiogenesis.
Topics: Animals; Apoptosis; Cell Cycle; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Survival; Female; Humans; Indoles; Mice; Mice, Nude; N-Myc Proto-Oncogene Protein; Neovascularization, Pathologic; Neuroblastoma; Nuclear Proteins; Oncogene Proteins; Proto-Oncogene Mas; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; Sunitinib | 2014 |
Optical tomography of MMP activity allows a sensitive noninvasive characterization of the invasiveness and angiogenesis of SCC xenografts.
Topics: Angiogenesis Inhibitors; Animals; Biomarkers, Tumor; Carcinoma, Squamous Cell; Female; Humans; Indoles; Matrix Metalloproteinases; Mice, Nude; Neovascularization, Pathologic; Pyrroles; Skin Neoplasms; Stromal Cells; Sunitinib; Tomography, Optical Coherence; Uterine Cervical Neoplasms; X-Ray Microtomography; Xenograft Model Antitumor Assays | 2014 |
Active angiogenesis in metastatic renal cell carcinoma predicts clinical benefit to sunitinib-based therapy.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Biomarkers, Tumor; Carcinoma, Renal Cell; Cohort Studies; Disease-Free Survival; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Microvessels; Middle Aged; Multivariate Analysis; Neovascularization, Pathologic; Phosphoproteins; Proportional Hazards Models; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
Determinants for in vivo antitumor effect of angiogenesis inhibitor SU5416 formulated in PEGylated emulsion.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Cell Line; Cell Line, Tumor; Emulsions; Endothelium, Vascular; Humans; Indoles; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Neoplasms; Neovascularization, Pathologic; Pharmaceutical Vehicles; Polyethylene Glycols; Protein Kinase Inhibitors; Pyrroles; Vascular Endothelial Growth Factor A | 2014 |
Combined effect of vascular-leakage-blocker Sac-1004 and antiangiogenic drug sunitinib on tumor angiogenesis.
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Drug Therapy, Combination; Indoles; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; Pyrroles; Saponins; Sunitinib | 2014 |
Both sunitinib and sorafenib are effective treatments for pheochromocytoma in a xenograft model.
Topics: Administration, Oral; Adrenal Gland Neoplasms; Angiogenesis Inhibitors; Animals; Apoptosis; Cell Survival; Dose-Response Relationship, Drug; Heterografts; Indoles; Male; Mice; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Niacinamide; PC12 Cells; Phenylurea Compounds; Pheochromocytoma; Protein Kinase Inhibitors; Pyrroles; Rats; Sorafenib; Sunitinib; Time Factors; Tumor Burden | 2014 |
Blocking lipid synthesis overcomes tumor regrowth and metastasis after antiangiogenic therapy withdrawal.
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Disease Progression; Fatty Acid Synthases; Homeodomain Proteins; Humans; Indoles; Lipids; Metabolomics; Mice; Mice, Inbred C57BL; Mice, Knockout; Neoplasm Metastasis; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Proteomics; Pyrroles; RNA Interference; Sorafenib; Sunitinib; Transplantation, Heterologous | 2014 |
Relationships between the effect of sunitinib and immature blood vessels in metastatic renal cell cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Blood Vessels; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Disease Progression; Disease-Free Survival; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Neovascularization, Pathologic; Nephrectomy; Pericytes; Platelet Endothelial Cell Adhesion Molecule-1; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Time Factors; Treatment Outcome | 2015 |
Lack of involvement of CEP adducts in TLR activation and in angiogenesis.
Topics: Animals; Choroidal Neovascularization; Disease Models, Animal; HEK293 Cells; Humans; Lasers; Leukocytes; Mice, Inbred C57BL; Neovascularization, Pathologic; Pyrroles; Retina; Toll-Like Receptor 2 | 2014 |
Dll4 blockade potentiates the anti-tumor effects of VEGF inhibition in renal cell carcinoma patient-derived xenografts.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Calcium-Binding Proteins; Carcinoma, Renal Cell; Cell Line, Tumor; Humans; Indoles; Intercellular Signaling Peptides and Proteins; Intracellular Signaling Peptides and Proteins; Kidney Neoplasms; Male; Membrane Proteins; Mice; Mice, SCID; Neovascularization, Pathologic; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Signal Transduction; Sunitinib; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2014 |
Effects of preset sequential administrations of sunitinib and everolimus on tumour differentiation in Caki-1 renal cell carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cell Differentiation; Drug Administration Schedule; Everolimus; Female; Humans; Indoles; Kidney Neoplasms; Mice; Mice, Nude; Neovascularization, Pathologic; Pyrroles; Sirolimus; Sunitinib; Xenograft Model Antitumor Assays | 2015 |
Sunitinib impedes brain tumor progression and reduces tumor-induced neurodegeneration in the microenvironment.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Astrocytes; Brain Neoplasms; Cell Death; Cell Line, Tumor; Cell Proliferation; Disease Progression; Endothelial Cells; Glioma; Humans; Indoles; Mice; Neovascularization, Pathologic; Neurodegenerative Diseases; Neurons; Neuroprotective Agents; Pyrroles; Rats; Rodentia; Sunitinib; Tumor Microenvironment; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
Atorvastatin regulates apoptosis in chronically ischemic myocardium.
Topics: Animals; Apoptosis; Atorvastatin; bcl-2-Associated X Protein; Caspase 3; Chronic Disease; Disease Models, Animal; Gene Expression Regulation, Developmental; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; MAP Kinase Signaling System; Metabolic Syndrome; Myocardial Ischemia; Myocardium; Neovascularization, Pathologic; Pyrroles; Swine; Swine, Miniature | 2015 |
Prostatic angiogenic responses in late life: antiangiogenic therapy influences and relation with the glandular microenvironment in the transgenic adenocarcinoma of mouse prostate (TRAMP) model.
Topics: 5-alpha Reductase Inhibitors; Adenocarcinoma; Angiogenesis Inhibitors; Animals; Blotting, Western; Cyclohexanes; Disease Models, Animal; Endostatins; Fibroblast Growth Factor 2; Finasteride; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; Indoles; Male; Mice; Mice, Transgenic; Neovascularization, Pathologic; O-(Chloroacetylcarbamoyl)fumagillol; Prostatic Neoplasms; Pyrroles; Sesquiterpenes; Tumor Microenvironment; Vascular Endothelial Growth Factor A | 2015 |
Inhibition of placental growth factor in renal cell carcinoma.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Renal Cell; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Indoles; Kidney Neoplasms; Mice, Nude; Neovascularization, Pathologic; Placenta Growth Factor; Pregnancy Proteins; Pyrroles; Sunitinib; Transcriptome; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Sunitinib microspheres based on [PDLLA-PEG-PDLLA]-b-PLLA multi-block copolymers for ocular drug delivery.
Topics: Administration, Ophthalmic; Angiogenesis Inhibitors; Animals; Chick Embryo; Chorioallantoic Membrane; Delayed-Action Preparations; Drug Carriers; Drug Delivery Systems; Drug Liberation; Indoles; Intravitreal Injections; Lactic Acid; Microscopy, Electron, Scanning; Microspheres; Neovascularization, Pathologic; Polyesters; Polyethylene Glycols; Polymers; Pyrroles; Solvents; Sunitinib; Time Factors | 2015 |
Angiostatic treatment prior to chemo- or photodynamic therapy improves anti-tumor efficacy.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Axitinib; Cell Line, Tumor; Chick Embryo; Combined Modality Therapy; Cymenes; Disease Models, Animal; Doxorubicin; Drug Synergism; Humans; Imidazoles; Indazoles; Indoles; Neoplasms; Neovascularization, Pathologic; Organometallic Compounds; Oxygen Consumption; Photochemotherapy; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Tumor Burden | 2015 |
Optimal treatment scheduling of ionizing radiation and sunitinib improves the antitumor activity and allows dose reduction.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Models, Animal; Humans; Indoles; Neovascularization, Pathologic; Pyrroles; Radiation Dosage; Radiation, Ionizing; Sunitinib; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Sunitinib reduces tumor hypoxia and angiogenesis, and radiosensitizes prostate cancer stem-like cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indoles; Male; Mice; Neoplastic Stem Cells; Neovascularization, Pathologic; Prostate; Prostatic Neoplasms; Pyrroles; Sunitinib; Treatment Outcome; Xenograft Model Antitumor Assays | 2015 |
[Antiangiogenic therapy of malignant pheochromocytoma and paraganglioma with the view to the recent scientific developments].
Topics: Adrenal Gland Neoplasms; Angiogenesis Inhibitors; Benzamides; Humans; Imatinib Mesylate; Indoles; Neovascularization, Pathologic; Paraganglioma; Pheochromocytoma; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sunitinib; Thalidomide | 2015 |
Sunitinib but not VEGF blockade inhibits cancer stem cell endothelial differentiation.
Topics: Angiogenesis Inhibitors; Animals; Basic Helix-Loop-Helix Transcription Factors; Bevacizumab; Cell Differentiation; Cell Hypoxia; Cell Proliferation; Cell Survival; Cells, Cultured; Endothelial Progenitor Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indoles; Mice, SCID; Neoplastic Stem Cells; Neovascularization, Pathologic; Neovascularization, Physiologic; Protein Kinase Inhibitors; Pyrroles; RNA Interference; Signal Transduction; Sunitinib; Time Factors; Transfection; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
Investigation of the Lack of Angiogenesis in the Formation of Lymph Node Metastases.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Colonic Neoplasms; Head and Neck Neoplasms; Humans; Indoles; Lymph Nodes; Lymphatic Metastasis; Mice; Neovascularization, Pathologic; Pyrroles; Sunitinib | 2015 |
miR-155 and miR-484 Are Associated with Time to Progression in Metastatic Renal Cell Carcinoma Treated with Sunitinib.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Renal Cell; Disease Progression; Female; Gene Expression Regulation, Neoplastic; Humans; Indoles; Kaplan-Meier Estimate; Male; MicroRNAs; Middle Aged; Neoplasm Metastasis; Neovascularization, Pathologic; Pyrroles; Sunitinib | 2015 |
Famitinib enhances nasopharyngeal cancer cell radiosensitivity by attenuating radiation-induced phosphorylation of platelet-derived growth factor receptor and c-kit and inhibiting microvessel formation.
Topics: Animals; Carcinoma; Cell Line, Tumor; Female; Humans; Indoles; Mice; Mice, Nude; Microvessels; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neovascularization, Pathologic; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrroles; Radiation Tolerance; Receptor, Platelet-Derived Growth Factor beta; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays | 2015 |
HIF-1 Dimerization Inhibitor Acriflavine Enhances Antitumor Activity of Sunitinib in Breast Cancer Model.
Topics: Acriflavine; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Disease Models, Animal; Drug Synergism; Female; Hypoxia-Inducible Factor 1; Indoles; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Myeloid Cells; Necrosis; Neovascularization, Pathologic; Protein Multimerization; Pyrroles; Spleen; Sunitinib; Transforming Growth Factor beta; Vascular Endothelial Growth Factor A | 2014 |
Invasiveness and metastasis of retinoblastoma in an orthotopic zebrafish tumor model.
Topics: Animals; Cell Line, Tumor; Disease Models, Animal; Heterografts; Humans; Indoles; Mice; Morpholinos; Neoplasm Invasiveness; Neoplasm Metastasis; Neovascularization, Pathologic; Pyrroles; Retinoblastoma; Sunitinib; Vascular Endothelial Growth Factor A; Zebrafish | 2015 |
miR-221/222 Are Involved in Response to Sunitinib Treatment in Metastatic Renal Cell Carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Biomarkers, Pharmacological; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Disease-Free Survival; Human Umbilical Vein Endothelial Cells; Humans; Indoles; Kidney Neoplasms; MicroRNAs; Middle Aged; Models, Statistical; Neovascularization, Pathologic; Prognosis; Pyrroles; Signal Transduction; Sunitinib; TOR Serine-Threonine Kinases; Transforming Growth Factor beta; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
NDRG1 overexpressing gliomas are characterized by reduced tumor vascularization and resistance to antiangiogenic treatment.
Topics: Angiogenesis Inhibitors; Animals; Brain Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Culture Media, Conditioned; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glioma; Human Umbilical Vein Endothelial Cells; Humans; Indoles; Intracellular Signaling Peptides and Proteins; Mice; Mutation; Neovascularization, Pathologic; Neovascularization, Physiologic; NF-kappa B; Promoter Regions, Genetic; Pyrroles; RNA Interference; Signal Transduction; Sunitinib; Time Factors; Transcription Factor AP-1; Transfection; Tumor Burden; Tumor Necrosis Factor Ligand Superfamily Member 15; Up-Regulation | 2016 |
Resistance to sunitinib in renal clear cell carcinoma results from sequestration in lysosomes and inhibition of the autophagic flux.
Topics: Angiogenesis Inhibitors; Autophagy; Carcinoma, Renal Cell; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Indoles; Lysosomes; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor A | 2015 |
Embolization biomaterial reinforced with nanotechnology for an in-situ release of anti-angiogenic agent in the treatment of hyper-vascularized tumors and arteriovenous malformations.
Topics: Acrylates; Angiogenesis Inhibitors; Animals; Arteriovenous Malformations; Biocompatible Materials; Cell Proliferation; Cells, Cultured; Cornea; Delayed-Action Preparations; Drug Compounding; Drug Delivery Systems; Embolization, Therapeutic; Endothelium, Vascular; Gels; Human Umbilical Vein Endothelial Cells; Indoles; Intercostal Muscles; Nanospheres; Neovascularization, Pathologic; Pyrroles; Rabbits; Random Allocation; Sheep, Domestic; Sunitinib | 2015 |
Preclinical Evidence That Trametinib Enhances the Response to Antiangiogenic Tyrosine Kinase Inhibitors in Renal Cell Carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Renal Cell; Cell Line, Tumor; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Drug Synergism; Endothelial Cells; Female; Humans; Indoles; Kidney Neoplasms; MAP Kinase Signaling System; Neovascularization, Pathologic; Protein Kinase Inhibitors; Pyridones; Pyrimidinones; Pyrroles; Sunitinib; Von Hippel-Lindau Tumor Suppressor Protein; Xenograft Model Antitumor Assays | 2016 |
Murine colitis treated with multitargeted tyrosine kinase inhibitors.
Topics: Animals; Axitinib; Colitis; Imidazoles; Indazoles; Indoles; Male; Mice; Mice, Inbred C57BL; Microvessels; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2016 |
Formononetin, a novel FGFR2 inhibitor, potently inhibits angiogenesis and tumor growth in preclinical models.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Aorta; Breast Neoplasms; Cell Proliferation; Chick Embryo; Chorioallantoic Membrane; Dose-Response Relationship, Drug; Female; Human Umbilical Vein Endothelial Cells; Humans; Indoles; Isoflavones; Male; MCF-7 Cells; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Neovascularization, Physiologic; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrroles; Rats, Sprague-Dawley; Receptor, Fibroblast Growth Factor, Type 2; Signal Transduction; STAT3 Transcription Factor; Sunitinib; Time Factors; Tumor Burden; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2015 |
Does angiogenesis play a role in the establishment of mesial temporal lobe epilepsy?
Topics: Angiogenesis Inhibitors; Animals; Cell Count; Disease Models, Animal; Epilepsy, Temporal Lobe; Hippocampus; Indoles; Lectins; Male; Neovascularization, Pathologic; Pilocarpine; Pyrroles; Rats; Rats, Sprague-Dawley; Statistics, Nonparametric; Sunitinib; Time Factors | 2016 |
Endoglin targeting inhibits tumor angiogenesis and metastatic spread in breast cancer.
Topics: Animals; Antibodies, Monoclonal; Breast Neoplasms; Endoglin; Female; Humans; Indoles; Neoplasm Metastasis; Neovascularization, Pathologic; Pyrroles; Smad1 Protein; Vascular Endothelial Growth Factor A; Zebrafish | 2016 |
Evaluation of polymorphisms in angiogenesis-related genes as predictive and prognostic markers for sunitinib-treated metastatic renal cell carcinoma patients.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neovascularization, Pathologic; Polymorphism, Single Nucleotide; Prognosis; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sunitinib; Vascular Endothelial Growth Factor A | 2016 |
Decreased apoptosis repressor with caspase recruitment domain confers resistance to sunitinib in renal cell carcinoma through alternate angiogenesis pathways.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Survival; Cytoskeletal Proteins; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Immunoblotting; Immunohistochemistry; Indoles; Kidney Neoplasms; Male; Microscopy, Confocal; Middle Aged; Neovascularization, Pathologic; Nerve Tissue Proteins; Pyrroles; RNA, Messenger; RNA, Small Interfering; Sunitinib; Vascular Endothelial Growth Factor A | 2016 |
Intrinsic resistance to sunitinib in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neovascularization, Pathologic; Prognosis; Pyrroles; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2017 |
The effect of macrophage and angiogenesis inhibition on the drug release and absorption from an intramuscular sustained-release paliperidone palmitate suspension.
Topics: Angiogenesis Inhibitors; Animals; Antipsychotic Agents; Clodronic Acid; Delayed-Action Preparations; Drug Liberation; Indoles; Injections, Intramuscular; Liposomes; Macrophages; Male; Neovascularization, Pathologic; Paliperidone Palmitate; Prodrugs; Pyrroles; Rats, Wistar; Sunitinib; Suspensions | 2016 |
Association of Angiopoietin-2 and Ki-67 Expression with Vascular Density and Sunitinib Response in Metastatic Renal Cell Carcinoma.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Female; Humans; Immunoenzyme Techniques; Indoles; Ki-67 Antigen; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Neovascularization, Pathologic; Prognosis; Pyrroles; Sunitinib; Survival Rate; Vesicular Transport Proteins | 2016 |
Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Female; Genotype; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neovascularization, Pathologic; Polymorphism, Single Nucleotide; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A | 2016 |
Inhibition of ALK1 signaling with dalantercept combined with VEGFR TKI leads to tumor stasis in renal cell carcinoma.
Topics: Activin Receptors, Type II; Animals; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carcinoma, Renal Cell; Cell Line, Tumor; Female; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Immunoglobulin Fc Fragments; Indazoles; Indoles; Kidney Neoplasms; Mice, Nude; Neovascularization, Pathologic; Protein Kinase Inhibitors; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Sunitinib; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
Novel therapeutic approaches and mechanisms in neuroendocrine tumors: the role of targeted agents.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Clinical Trials as Topic; Everolimus; Humans; Indoles; Molecular Targeted Therapy; Neoplasm Grading; Neovascularization, Pathologic; Neuroendocrine Tumors; Phosphatidylinositol 3-Kinases; Positron-Emission Tomography; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Pyrroles; Signal Transduction; Somatostatin; Sunitinib; TOR Serine-Threonine Kinases; Tuberous Sclerosis Complex 2 Protein; Tumor Suppressor Proteins | 2016 |
The pancreatic niche inhibits the effectiveness of sunitinib treatment of pancreatic cancer.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Indoles; Mice; Neovascularization, Pathologic; Pancreatic Neoplasms; Pyrroles; Sunitinib | 2016 |
Everolimus affects vasculogenic mimicry in renal carcinoma resistant to sunitinib.
Topics: Angiogenesis Inhibitors; Animals; Axitinib; Carcinoma, Renal Cell; Disease Models, Animal; Disease Progression; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Mice; Mice, Nude; Neovascularization, Pathologic; Pyrroles; Random Allocation; Sunitinib; Xenograft Model Antitumor Assays | 2016 |
MEK inhibition abrogates sunitinib resistance in a renal cell carcinoma patient-derived xenograft model.
Topics: Adult; Animals; Benzamides; Carcinoma, Renal Cell; Cell Line, Tumor; Diphenylamine; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Indoles; Kidney Neoplasms; Male; MAP Kinase Signaling System; Mice; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Mitogen-Activated Protein Kinase Kinases; Myeloid-Derived Suppressor Cells; Neoplasm Proteins; Neovascularization, Pathologic; Phosphorylation; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Pyrroles; Receptors, Interleukin-2; Sunitinib; Tumor Burden; Tumor Escape; Xenograft Model Antitumor Assays | 2016 |
In vitro and in vivo activities of an antitumor peptide HM-3: A special dose-efficacy relationship on an HCT‑116 xenograft model in nude mice.
Topics: Angiogenesis Inhibitors; Animals; Cell Movement; Cell Proliferation; Colorectal Neoplasms; Dose-Response Relationship, Drug; HCT116 Cells; Humans; Indoles; Mice; Neovascularization, Pathologic; Peptides; Pyrroles; Sunitinib; Xenograft Model Antitumor Assays | 2016 |
2-(ω-Carboxyethyl)pyrrole Antibody as a New Inhibitor of Tumor Angiogenesis and Growth.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Division; Cell Line, Tumor; Female; Humans; Mice; Mice, Nude; Neovascularization, Pathologic; Pyrroles; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2017 |
Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models.
Topics: Angiogenesis Inhibitors; Capillaries; Humans; Immunotherapy; Indoles; Lung Neoplasms; Models, Biological; Neovascularization, Pathologic; Pyrroles; Sunitinib | 2017 |
Discovery and preclinical evaluation of 7-benzyl-N-(substituted)-pyrrolo[3,2-d]pyrimidin-4-amines as single agents with microtubule targeting effects along with triple-acting angiokinase inhibition as antitumor agents.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Cell Line; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Microtubules; Molecular Docking Simulation; Molecular Structure; Neovascularization, Pathologic; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptor Protein-Tyrosine Kinases; Structure-Activity Relationship | 2017 |
An exploratory association of polymorphisms in angiogenesis-related genes with susceptibility, clinical response and toxicity in gastrointestinal stromal tumors receiving sunitinib after imatinib failure.
Topics: Adult; Aged; Aged, 80 and over; Demography; Disease Progression; Female; Gastrointestinal Stromal Tumors; Genetic Association Studies; Genetic Predisposition to Disease; Haplotypes; Humans; Imatinib Mesylate; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Neovascularization, Pathologic; Polymorphism, Single Nucleotide; Pyrroles; Sunitinib; Time Factors; Treatment Failure; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-3; Young Adult | 2017 |
Synthesis of Novel c(AmpRGD)-Sunitinib Dual Conjugates as Molecular Tools Targeting the α
Topics: Angiogenesis Inhibitors; Animals; Cell Line; Humans; Indoles; Integrin alphaVbeta3; Mice; Neoplasms, Experimental; Neovascularization, Pathologic; Oligopeptides; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor Receptor-2 | 2017 |
A Study of Angiogenesis Markers in Patients with Renal Cell Carcinoma Undergoing Therapy with Sunitinib.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antigens, Neoplasm; Becaplermin; Biomarkers, Tumor; Carbonic Anhydrase IX; Carcinoma, Renal Cell; Cyclin D1; Disease-Free Survival; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Neovascularization, Pathologic; Proto-Oncogene Proteins c-sis; Pyrroles; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2017 |
The Role of Vascular Endothelial Growth Factor in Small-airway Remodelling in a Rat Model of Chronic Obstructive Pulmonary Disease.
Topics: Airway Remodeling; Angiogenesis Inhibitors; Animals; Disease Models, Animal; Indoles; Lipopolysaccharides; Male; Neovascularization, Pathologic; Nicotiana; Pulmonary Disease, Chronic Obstructive; Pyrroles; Rats, Sprague-Dawley; Smoke; Sunitinib; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2017 |
Treatment Of Sunitinib-Induced Hypertension In Solid Tumors By Nitric Oxid Donors.
Topics: Female; Humans; Hypertension; Indoles; Male; Neoplasms; Neovascularization, Pathologic; Nitric Oxide Donors; Pyrroles; Sunitinib | 2015 |
Novel 6-methoxycarbonyl indolinones bearing a pyrrole Mannich base moiety as angiokinase inhibitors.
Topics: Apoptosis; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans; Indoles; Inhibitory Concentration 50; Mannich Bases; Molecular Docking Simulation; Neovascularization, Pathologic; Protein Kinase Inhibitors; Protein Kinases; Pyrroles; Receptor, Platelet-Derived Growth Factor beta; Vascular Endothelial Growth Factor A | 2017 |
Anti-angiogenic treatment promotes triple-negative breast cancer invasion via vasculogenic mimicry.
Topics: Adult; Aged; Angiogenesis Inhibitors; Animals; Antigens, CD; Breast; Cadherins; Cell Line, Tumor; Female; Fluorescent Antibody Technique; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indoles; Matrix Metalloproteinase 2; Mice; Mice, Inbred BALB C; Mice, Nude; Microcirculation; Middle Aged; Neoplasm Invasiveness; Neovascularization, Pathologic; Nuclear Proteins; Pyrroles; Sunitinib; Tissue Array Analysis; Treatment Outcome; Triple Negative Breast Neoplasms; Twist-Related Protein 1; Up-Regulation; Xenograft Model Antitumor Assays | 2017 |
[Effect of Endostatin and SU6668 combined with 5-FU on human colon cancer xenograft in nude mice].
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Colonic Neoplasms; Endostatins; Fluorouracil; Humans; Indoles; Lymphatic Metastasis; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Oxindoles; Propionates; Pyrroles | 2008 |
Hypoxia-induced retinal angiogenesis in zebrafish as a model to study retinopathy.
Topics: Angiogenesis Inhibitors; Animals; Disease Models, Animal; Green Fluorescent Proteins; Humans; Hypoxia; Indoles; Microscopy, Confocal; Neovascularization, Pathologic; Pyrroles; Receptors, Notch; Retinal Diseases; Retinal Neovascularization; Signal Transduction; Sunitinib; Vascular Endothelial Growth Factor A; Zebrafish | 2008 |
VEGFR-2 antagonist SU5416 attenuates bleomycin-induced pulmonary fibrosis in mice.
Topics: Angiogenesis Inhibitors; Animals; Antibiotics, Antineoplastic; Bleomycin; Blotting, Western; Bronchoalveolar Lavage Fluid; Flow Cytometry; Hydroxyproline; Indoles; Lung; Male; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; Pulmonary Fibrosis; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Smad3 Protein; Transforming Growth Factor beta1; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2009 |
Nonclinical safety evaluation of sunitinib: a potent inhibitor of VEGF, PDGF, KIT, FLT3, and RET receptors.
Topics: Adrenal Glands; Animals; Antineoplastic Agents; Bone Marrow; Female; Gastrointestinal Tract; Growth Plate; Incisor; Indoles; Lymphoid Tissue; Macaca fascicularis; Male; Microscopy, Electron; Neovascularization, Pathologic; Ovary; Pancreas; Pyrroles; Rats; Rats, Sprague-Dawley; Receptor Protein-Tyrosine Kinases; Recovery of Function; Signal Transduction; Sunitinib; Toxicity Tests, Chronic | 2008 |
Targeting transforming growth factor (TGF)-betaRI inhibits activation of beta1 integrin and blocks vascular invasion in hepatocellular carcinoma.
Topics: Aged; Cadherins; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cells, Cultured; Endothelium, Vascular; Enzyme Inhibitors; Extracellular Matrix Proteins; Female; Humans; Integrin alpha5beta1; Integrin beta1; Liver Neoplasms; Male; Neovascularization, Pathologic; Protein Serine-Threonine Kinases; Pyrazoles; Pyrroles; Receptor, Transforming Growth Factor-beta Type I; Receptors, Transforming Growth Factor beta; Smad2 Protein; Smad3 Protein; Transforming Growth Factor beta1 | 2009 |
From theoretical synergy to clinical supra-additive toxicity.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Drug Synergism; Humans; Hypertension; Indoles; Kidney Neoplasms; Neovascularization, Pathologic; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor A | 2009 |
VEGF and angiogenesis in acute and chronic MOG((35-55)) peptide induced EAE.
Topics: Angiogenesis Inhibitors; Angiogenic Proteins; Animals; Blood Vessels; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Female; Glycoproteins; Indoles; Laminin; Mice; Mice, Inbred C57BL; Myelin Sheath; Myelin-Oligodendrocyte Glycoprotein; Neovascularization, Pathologic; Peptide Fragments; Pyrroles; RNA, Messenger; Spinal Cord; Up-Regulation; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Wallerian Degeneration | 2009 |
Oral administration of pyrrolidine dithiocarbamate (PDTC) inhibits VEGF expression, tumor angiogenesis, and growth of breast cancer in female mice.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Synergism; Estrogen Receptor alpha; Female; Gene Expression Regulation, Neoplastic; Humans; Indoles; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; NF-kappa B; Pyrroles; Pyrrolidines; Thiocarbamates; Tumor Burden; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2009 |
Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Basic Helix-Loop-Helix Transcription Factors; Carcinoma, Renal Cell; Cell Growth Processes; Cell Line, Tumor; Female; Humans; Indoles; Kidney Neoplasms; Mice; Neovascularization, Pathologic; Pyrroles; Signal Transduction; STAT3 Transcription Factor; Sunitinib; Von Hippel-Lindau Tumor Suppressor Protein | 2009 |
Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis.
Topics: Angiogenesis Inhibitors; Animals; Humans; Indoles; Mice; Neoplasm Metastasis; Neoplasms; Neovascularization, Pathologic; Pyrroles; Sunitinib; Xenograft Model Antitumor Assays | 2009 |
Sunitinib prolongs survival in genetically engineered mouse models of multistep lung carcinogenesis.
Topics: AMP-Activated Protein Kinases; Angiogenesis Inhibitors; Animals; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Disease Models, Animal; Genetic Engineering; Immunohistochemistry; Indoles; Lung Neoplasms; Mice; Mutation; Neoplasm Metastasis; Neovascularization, Pathologic; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins p21(ras); Pyrroles; Sunitinib | 2009 |
Hemangiopericytoma and antiangiogenic therapy: clinical benefit of antiangiogenic therapy (sorafenib and sunitinib) in relapsed malignant haemangioperyctoma /solitary fibrous tumour.
Topics: Aged; Angiogenesis Inhibitors; Benzenesulfonates; Fatal Outcome; Female; Hemangiopericytoma; Humans; Indoles; Middle Aged; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Recurrence; Solitary Fibrous Tumors; Sorafenib; Sunitinib; Tomography, X-Ray Computed; Ultrasonography | 2010 |
Theranostic strategy against plaque angiogenesis.
Topics: Angiogenesis Inhibitors; Animals; Atherosclerosis; Atorvastatin; Carbocyanines; Cyclohexanes; Drug Carriers; Drug Synergism; Drug Therapy, Combination; Fatty Acids, Unsaturated; Heptanoic Acids; Heterocyclic Compounds, 1-Ring; Humans; Integrin alphaVbeta3; Magnetic Resonance Imaging; Nanoparticles; Neovascularization, Pathologic; Pyrroles; Sesquiterpenes; Time Factors | 2008 |
Antiangiogenic synergism of integrin-targeted fumagillin nanoparticles and atorvastatin in atherosclerosis.
Topics: Angiogenesis Inhibitors; Animals; Aorta, Thoracic; Atherosclerosis; Atorvastatin; Carbocyanines; Cyclohexanes; Disease Models, Animal; Drug Carriers; Drug Synergism; Drug Therapy, Combination; Fatty Acids, Unsaturated; Heptanoic Acids; Heterocyclic Compounds, 1-Ring; Integrin alphaVbeta3; Liver; Magnetic Resonance Imaging; Nanoparticles; Neovascularization, Pathologic; Pyrroles; Rabbits; Sesquiterpenes; Time Factors | 2008 |
Inhibition of tyrosine kinase receptors by SU6668 promotes abnormal stromal development at the periphery of carcinomas.
Topics: Animals; Carcinoma; Cell Proliferation; Colonic Neoplasms; Disease Progression; HT29 Cells; Humans; Indoles; Magnetic Resonance Imaging; Mice; Mice, Nude; Neovascularization, Pathologic; Oxindoles; Propionates; Pyrroles; Receptor Protein-Tyrosine Kinases; Stromal Cells; Up-Regulation; Xenograft Model Antitumor Assays | 2009 |
Assessment of vascular remodeling under antiangiogenic therapy using DCE-MRI and vessel size imaging.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Blood Vessels; Carcinoma, Squamous Cell; Contrast Media; Female; Indoles; Magnetic Resonance Imaging; Mice; Mice, Nude; Neovascularization, Pathologic; Pyrroles; Sunitinib; Treatment Outcome | 2009 |
In vivo antitumor and antimetastatic activity of sunitinib in preclinical neuroblastoma mouse model.
Topics: Angiogenesis Inhibitors; Animals; Blotting, Western; Cell Line, Tumor; Disease Models, Animal; Gene Expression; Humans; Immunohistochemistry; Indoles; Mice; Neovascularization, Pathologic; Neuroblastoma; Oligonucleotide Array Sequence Analysis; Pyrroles; Sunitinib; Xenograft Model Antitumor Assays | 2009 |
Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Drug Resistance, Neoplasm; Drug Synergism; Humans; Indoles; Male; Mice; Mice, Nude; Neoplasms, Germ Cell and Embryonal; Neovascularization, Pathologic; Pyrroles; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Reverse Transcriptase Polymerase Chain Reaction; Sunitinib; Survival Analysis; Testicular Neoplasms; Tumor Burden; Xenograft Model Antitumor Assays | 2009 |
Targeting both HIF-1 and HIF-2 in human colon cancer cells improves tumor response to sunitinib treatment.
Topics: Animals; Antineoplastic Agents; Basic Helix-Loop-Helix Transcription Factors; Cell Line, Tumor; Colonic Neoplasms; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Knockout Techniques; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indoles; Mice; Mice, Nude; Neovascularization, Pathologic; Pyrroles; Sunitinib; Xenograft Model Antitumor Assays | 2009 |
Antiangiogenic versus cytotoxic therapeutic approaches in a mouse model of pancreatic cancer: an experimental study with a multitarget tyrosine kinase inhibitor (sunitinib), gemcitabine and radiotherapy.
Topics: Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspase 3; Cell Line, Tumor; Chemotherapy, Adjuvant; Deoxycytidine; Epidermal Growth Factor; fas Receptor; Gemcitabine; Indoles; Male; Mice; Microvessels; Neovascularization, Pathologic; Pancreatic Neoplasms; Placenta Growth Factor; Pregnancy Proteins; Protein Kinase Inhibitors; Pyrroles; Radiotherapy, Adjuvant; Sunitinib; Time Factors; Vascular Endothelial Growth Factor A | 2009 |
Reduction in endothelial tip cell filopodia corresponds to reduced intravitreous but not intraretinal vascularization in a model of ROP.
Topics: Angiogenesis Inhibitors; Animals; Animals, Newborn; Caspase 3; Cell Movement; Cells, Cultured; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelial Cells; Humans; Indoles; Infant, Newborn; Integrin beta3; Neovascularization, Pathologic; Phosphorylation; Protein Kinase Inhibitors; Pseudopodia; Pyrroles; Rats; Rats, Sprague-Dawley; Retinal Vessels; Retinopathy of Prematurity; Time Factors; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2; Vitreous Body | 2009 |
Liver cyst cytokines promote endothelial cell proliferation and development.
Topics: Animals; Cell Proliferation; Cells, Cultured; Cyst Fluid; Cysts; Cytokines; Disease Models, Animal; Endothelial Cells; Endothelium, Vascular; Enzyme Inhibitors; Humans; Indoles; Liver Diseases; Mice; Mice, Inbred C57BL; Mice, Knockout; Neovascularization, Pathologic; NIMA-Interacting Peptidylprolyl Isomerase; Peptidylprolyl Isomerase; Phosphorylation; Polycystic Kidney, Autosomal Dominant; Pyrroles; TRPP Cation Channels; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2009 |
Inhibition of transforming growth factor beta receptor I kinase blocks hepatocellular carcinoma growth through neo-angiogenesis regulation.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Chick Embryo; Embryonic Development; Humans; Liver Neoplasms; Neovascularization, Pathologic; Protein Serine-Threonine Kinases; Pyrazoles; Pyrroles; Receptor, Transforming Growth Factor-beta Type I; Receptors, Transforming Growth Factor beta; Signal Transduction; Smad Proteins; Transforming Growth Factor beta1; Vascular Endothelial Growth Factor A | 2009 |
Dynamic contrast-enhanced magnetic resonance imaging of vascular changes induced by sunitinib in papillary renal cell carcinoma xenograft tumors.
Topics: Animals; Antineoplastic Agents; Capillary Permeability; Carcinoma, Renal Cell; Contrast Media; Female; Gadolinium DTPA; Humans; Hypoxia; Immunoprecipitation; Indoles; Kidney Neoplasms; Magnetic Resonance Imaging; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Pyrroles; Receptors, Platelet-Derived Growth Factor; Sunitinib; Tumor Cells, Cultured; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2009 |
Estimation of tumor microvessel density by MRI using a blood pool contrast agent.
Topics: Angiogenesis Inhibitors; Animals; Artifacts; Blood Volume; Carcinoma, Squamous Cell; Cerebrovascular Circulation; Contrast Media; Dextrans; Female; Ferrosoferric Oxide; Indoles; Injections, Intravenous; Magnetic Resonance Angiography; Magnetite Nanoparticles; Mice; Mice, Inbred C3H; Microvessels; Neovascularization, Pathologic; Phantoms, Imaging; Predictive Value of Tests; Pyrroles; Soft Tissue Neoplasms; Sunitinib | 2009 |
Sunitinib (SUTENT, SU11248) suppresses tumor growth and induces apoptosis in xenograft models of human hepatocellular carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Bevacizumab; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Hep G2 Cells; Humans; Indoles; Liver Neoplasms; Liver Neoplasms, Experimental; Mice; Mice, SCID; Neovascularization, Pathologic; Phosphorylation; Pyrroles; Sunitinib; Xenograft Model Antitumor Assays | 2009 |
Effects of atorvastatin on circulating CD34+/CD133+/ CD45- progenitor cells and indices of angiogenesis (vascular endothelial growth factor and the angiopoietins 1 and 2) in atherosclerotic vascular disease and diabetes mellitus.
Topics: Aged; Angiopoietin-1; Angiopoietin-2; Antigens, CD; Antigens, CD34; Atherosclerosis; Atorvastatin; Diabetes Mellitus; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leukocyte Common Antigens; Male; Middle Aged; Neovascularization, Pathologic; Prospective Studies; Pyrroles; Stem Cells; Vascular Endothelial Growth Factor A | 2010 |
MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer.
Topics: Angiogenesis Inhibitors; Animals; Cell Differentiation; Cell Proliferation; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Indoles; Mice; Mice, Inbred C57BL; MicroRNAs; Neovascularization, Pathologic; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sunitinib; Tumor Cells, Cultured | 2009 |
Everolimus: in advanced renal cell carcinoma.
Topics: Benzenesulfonates; Carcinoma, Renal Cell; Cell Proliferation; Clinical Trials, Phase III as Topic; Disease-Free Survival; Double-Blind Method; Everolimus; Humans; Immunosuppressive Agents; Indoles; Kidney Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Placebos; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome | 2009 |
Atorvastatin inhibits inflammatory angiogenesis in mice through down regulation of VEGF, TNF-alpha and TGF-beta1.
Topics: Administration, Oral; Animals; Atorvastatin; Disease Models, Animal; Dose-Response Relationship, Drug; Down-Regulation; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Macrophages; Male; Mice; Neovascularization, Pathologic; Pyrroles; Transforming Growth Factor beta1; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A | 2010 |
Sunitinib paves the way for targeted therapies in neuroendocrine tumors.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoid Tumor; Cell Line, Tumor; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Melphalan; Neovascularization, Pathologic; Neuroendocrine Tumors; Pancreatic Neoplasms; Procarbazine; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrroles; Sunitinib; Vinblastine; Xenograft Model Antitumor Assays | 2009 |
TSU68, an antiangiogenic receptor tyrosine kinase inhibitor, induces tumor vascular normalization in a human cancer xenograft nude mouse model.
Topics: Angiogenesis Inhibitors; Animals; Colon; Colonic Neoplasms; Disease Models, Animal; Drug Delivery Systems; Humans; Indoles; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Neovascularization, Physiologic; Oxindoles; Propionates; Pyrroles; Receptors, Fibroblast Growth Factor; Receptors, Platelet-Derived Growth Factor; Sensitivity and Specificity; Transplantation, Heterologous; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2009 |
Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Blotting, Western; Carcinoma, Renal Cell; Cell Line; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dose-Response Relationship, Drug; Endothelial Cells; Endothelium, Vascular; Female; Humans; Indoles; Kidney Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Pyrroles; Receptor, Platelet-Derived Growth Factor beta; RNA Interference; Sunitinib; Tumor Burden; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2010 |
MGMT modulates glioblastoma angiogenesis and response to the tyrosine kinase inhibitor sunitinib.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Cell Separation; Combined Modality Therapy; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Gene Expression; Gene Expression Profiling; Glioblastoma; Humans; Indoles; Mice; Mice, Nude; Neovascularization, Pathologic; Protein Kinase Inhibitors; Pyrroles; Radiotherapy; Reverse Transcriptase Polymerase Chain Reaction; Sunitinib; Temozolomide; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2010 |
Multiple receptor tyrosine kinases regulate HIF-1alpha and HIF-2alpha in normoxia and hypoxia in neuroblastoma: implications for antiangiogenic mechanisms of multikinase inhibitors.
Topics: Angiogenesis Inhibitors; Animals; Basic Helix-Loop-Helix Transcription Factors; Blotting, Western; Cell Movement; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Immunoenzyme Techniques; Indoles; Mice; Mice, Inbred NOD; Mice, SCID; Neovascularization, Pathologic; Neuroblastoma; Proto-Oncogene Proteins c-kit; Proto-Oncogene Proteins c-ret; Pyrroles; Receptor Protein-Tyrosine Kinases; Receptor, Platelet-Derived Growth Factor beta; Receptors, Interleukin-2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Sunitinib; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-3; Xenograft Model Antitumor Assays | 2010 |
Targeting the Transforming Growth Factor-beta pathway inhibits human basal-like breast cancer metastasis.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Female; Humans; Mice; Mice, Nude; Neoplasm Metastasis; Neovascularization, Pathologic; Pyrazoles; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Transforming Growth Factor beta; Xenograft Model Antitumor Assays | 2010 |
SU11248, a selective tyrosine kinases inhibitor suppresses breast tumor angiogenesis and growth via targeting both tumor vasculature and breast cancer cells.
Topics: Angiogenesis Inhibitors; Animals; Breast Neoplasms; Cell Line; Cell Line, Tumor; Cell Proliferation; Female; Gene Expression Profiling; Humans; Immunohistochemistry; Indoles; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; Platelet Endothelial Cell Adhesion Molecule-1; Protein Kinase Inhibitors; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; Sunitinib; Tumor Burden; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2010 |
Deciphering the anticancer mechanisms of sunitinib.
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Cell Proliferation; Female; Gene Expression Profiling; Indoles; Mammary Neoplasms, Experimental; Mice; Models, Biological; Neovascularization, Pathologic; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Tumor Burden; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2010 |
Oxidative stress induces angiogenesis by activating TLR2 with novel endogenous ligands.
Topics: Aging; Animals; Aorta; Cell Line; Cell Movement; Endothelial Cells; Hindlimb; Humans; Immunity, Innate; Inflammation; Ischemia; Ligands; Melanoma; Mice; Mice, Inbred C57BL; Myeloid Differentiation Factor 88; Neovascularization, Pathologic; Neovascularization, Physiologic; Oxidation-Reduction; Oxidative Stress; Platelet Endothelial Cell Adhesion Molecule-1; Propionates; Pyrroles; rac1 GTP-Binding Protein; Receptors, Scavenger; Signal Transduction; Toll-Like Receptor 2; Toll-Like Receptor 4; Vascular Endothelial Growth Factor A; Wound Healing | 2010 |
Sunitinib (SU11248) inhibits growth of human ovarian cancer in xenografted mice.
Topics: Animals; Antineoplastic Agents; Disease Progression; Female; Humans; Immunohistochemistry; Indoles; Mice; Mice, SCID; Neovascularization, Pathologic; Ovarian Neoplasms; Pyrroles; Sunitinib; Xenograft Model Antitumor Assays | 2010 |
HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors.
Topics: Angiogenesis Inhibitors; Animals; Drug Resistance, Neoplasm; Hepatocyte Growth Factor; Humans; Indoles; Mice; Mice, Nude; Neoplasms, Experimental; Neovascularization, Pathologic; NIH 3T3 Cells; Proto-Oncogene Proteins c-met; Pyrroles; Signal Transduction; Sunitinib; Transfection | 2010 |
Enhanced angiogenic capacity of human umbilical vein endothelial cells from women with preeclampsia.
Topics: Adult; Analysis of Variance; Angiogenesis Inhibitors; Case-Control Studies; Cell Hypoxia; Cells, Cultured; Endothelial Cells; Female; Humans; Indoles; Neovascularization, Pathologic; Neovascularization, Physiologic; Pre-Eclampsia; Pregnancy; Protein Kinase Inhibitors; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Umbilical Veins; Young Adult | 2011 |
Stress-sensing toll-like receptor as a driver of angiogenesis.
Topics: Animals; Antibodies, Neutralizing; Humans; Immunity; Models, Biological; Neovascularization, Pathologic; Pyrroles; Receptors, Pattern Recognition; Stress, Physiological; Toll-Like Receptors | 2011 |
Atorvastatin inhibits plaque development and adventitial neovascularization in ApoE deficient mice independent of plasma cholesterol levels.
Topics: Angiogenesis Inhibitors; Animals; Apolipoproteins E; Atherosclerosis; Atorvastatin; Cell Line; Cell Proliferation; Cholesterol; Connective Tissue; Disease Models, Animal; Endothelial Cells; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mice; Mice, Knockout; Microvessels; Neovascularization, Pathologic; Platelet Endothelial Cell Adhesion Molecule-1; Pyrroles; Time Factors | 2011 |
Augmentation of chemotherapeutic infusion effect by TSU-68, an oral targeted antiangiogenic agent, in a rabbit VX2 liver tumor model.
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Disease Models, Animal; Doxorubicin; Drug Therapy, Combination; Ethiodized Oil; Indoles; Infusions, Intravenous; Liver Neoplasms, Experimental; Neovascularization, Pathologic; Oxindoles; Propionates; Pyrroles; Rabbits; Statistics, Nonparametric; Tomography, X-Ray Computed | 2012 |
Pleiotropic stromal effects of vascular endothelial growth factor receptor 2 antibody therapy in renal cell carcinoma models.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Renal Cell; Disease Models, Animal; Drug Interactions; Female; Humans; Hypoxia-Inducible Factor 1; Indoles; Kidney Neoplasms; Lymphatic Vessels; Mice; Mice, Nude; Mutation; Neoplasm Transplantation; Neovascularization, Pathologic; Pericytes; Pyrroles; Stromal Cells; Sunitinib; Tumor Burden; Tumor Cells, Cultured; Vascular Endothelial Growth Factor Receptor-2; Von Hippel-Lindau Tumor Suppressor Protein | 2011 |
Effects of targeting the VEGF and PDGF pathways in diffuse orthotopic glioma models.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Blood-Brain Barrier; Brain Neoplasms; Glioma; Humans; Indoles; Magnetic Resonance Imaging; Mice; Mice, Nude; Neovascularization, Pathologic; Piperidines; Pyrroles; Quinazolines; Receptor, Platelet-Derived Growth Factor beta; Signal Transduction; Sunitinib; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2011 |
VEGFR1 and PKCα signaling control melanoma vasculogenic mimicry in a VEGFR2 kinase-independent manner.
Topics: Animals; Cell Line, Tumor; Female; Humans; Indoles; Melanoma; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; Protein Kinase C-alpha; Pyrroles; RNA, Small Interfering; Signal Transduction; Skin Neoplasms; Transfection; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2011 |
A one-pot synthesis and biological activity of ageladine A and analogues.
Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans; Inhibitory Concentration 50; Matrix Metalloproteinase Inhibitors; Neovascularization, Pathologic; Protein Kinase Inhibitors; Protein Kinases; Pyrroles | 2011 |
SU5416 and EGCG work synergistically and inhibit angiogenic and survival factors and induce cell cycle arrest to promote apoptosis in human malignant neuroblastoma SH-SY5Y and SK-N-BE2 cells.
Topics: Angiogenesis Inhibitors; Anticarcinogenic Agents; Apoptosis; Catechin; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Survival; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase Inhibitor p21; E2F1 Transcription Factor; Humans; In Situ Nick-End Labeling; Indoles; Neovascularization, Pathologic; Neuroblastoma; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Retinoblastoma Protein; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2011 |
Sunitinib suppresses tumor growth and metastases in a highly metastatic mouse mammary cancer model.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Blotting, Western; Body Weight; Female; Humans; Immunoenzyme Techniques; Indoles; Lymphatic Metastasis; Lymphatic Vessels; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Phosphorylation; Pyrroles; Sunitinib; Tumor Cells, Cultured; Tyrosine; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2011 |
Antitumor and antiangiogenic activities of BMS-690514, an inhibitor of human EGF and VEGF receptor kinase families.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Cell Line; Cell Proliferation; Endothelial Cells; ErbB Receptors; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Neovascularization, Pathologic; Piperidines; Pyrroles; Receptor, ErbB-2; Receptors, Vascular Endothelial Growth Factor; Regional Blood Flow; Signal Transduction; Triazines; Xenograft Model Antitumor Assays | 2011 |
Pyrrolo[2,3-α]carbazole derivatives as topoisomerase I inhibitors that affect viability of glioma and endothelial cells in vitro and angiogenesis in vivo.
Topics: Angiogenesis Inhibitors; Animals; Carbazoles; Cell Line, Tumor; Cell Proliferation; Chick Embryo; Chorioallantoic Membrane; DNA Topoisomerases, Type I; Endothelial Cells; Glioma; Humans; Neovascularization, Pathologic; Neovascularization, Physiologic; Pyrroles; Rats; Topoisomerase I Inhibitors | 2011 |
Vasculatures in tumors growing from preirradiated tissues: formed by vasculogenesis and resistant to radiation and antiangiogenic therapy.
Topics: Angiogenesis Inhibitors; Animals; Bone Marrow Transplantation; Cell Aggregation; Cell Hypoxia; Cell Line, Tumor; Coloring Agents; Drug Resistance, Neoplasm; Endothelial Cells; Green Fluorescent Proteins; Indoles; Macrophages; Male; Mice; Mice, Inbred C57BL; Neoplasm Recurrence, Local; Neoplasms, Radiation-Induced; Neovascularization, Pathologic; Nitroimidazoles; Prostatic Neoplasms; Pyrroles; Radiation Dosage; Radiation Tolerance; Radiation-Sensitizing Agents; Salvage Therapy; Sunitinib; Tumor Burden; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2011 |
Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor 3.
Topics: Angiogenesis Inhibitors; Animals; Cell Movement; Endothelial Cells; Female; Humans; Indoles; Lymphangiogenesis; Lymphatic Metastasis; Lymphatic Vessels; Mammary Neoplasms, Experimental; Mice; Neovascularization, Pathologic; Phosphorylation; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor C; Vascular Endothelial Growth Factor D; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factor Receptor-3 | 2011 |
A novel xenograft model in zebrafish for high-resolution investigating dynamics of neovascularization in tumors.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Endothelial Cells; Humans; Indoles; Mice; Microvessels; Neoplasms; Neovascularization, Pathologic; Pyrroles; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays; Zebrafish | 2011 |
Tumor kinase activity in locally advanced rectal cancer: angiogenic signaling and early systemic dissemination.
Topics: Adult; Aged; Analysis of Variance; Bone Marrow Cells; Cell Hypoxia; Female; Humans; Immunomagnetic Separation; Indoles; Male; Middle Aged; Neoplastic Cells, Circulating; Neovascularization, Pathologic; Phosphopeptides; Phosphorylation; Protein-Tyrosine Kinases; Pyrroles; Rectal Neoplasms; Signal Transduction; Sunitinib | 2011 |
Comparing the efficacy of sunitinib with sorafenib in xenograft models of human hepatocellular carcinoma: mechanistic explanation.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Humans; Indoles; Liver Neoplasms; Male; MAP Kinase Signaling System; Mice; Mice, SCID; Neoplasm Proteins; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Random Allocation; Sorafenib; Sunitinib; Xenograft Model Antitumor Assays | 2011 |
Complementary information from magnetic resonance imaging and (18)F-fluoromisonidazole positron emission tomography in the assessment of the response to an antiangiogenic treatment in a rat brain tumor model.
Topics: Angiogenesis Inhibitors; Animals; Biological Transport; Brain; Brain Neoplasms; Cell Hypoxia; Cell Line, Tumor; Cerebrovascular Circulation; Disease Models, Animal; Glioma; Indoles; Kinetics; Magnetic Resonance Imaging; Misonidazole; Neovascularization, Pathologic; Permeability; Positron-Emission Tomography; Pyrroles; Rats; Sunitinib; Treatment Outcome | 2011 |
Sunitinib inhibits tumor vascularity and growth but does not affect Akt and ERK phosphorylation in xenograft tumors.
Topics: Angiogenesis Inhibitors; Angiogenic Proteins; Animals; Cell Growth Processes; Disease Models, Animal; Extracellular Signal-Regulated MAP Kinases; Female; HEK293 Cells; Humans; Indoles; Mice; Mice, Inbred NOD; Mice, SCID; Microvessels; Neoplasms, Experimental; Neovascularization, Pathologic; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyrroles; Random Allocation; Sunitinib; Xenograft Model Antitumor Assays | 2011 |
Antiangiogenic agent sunitinib transiently increases tumor oxygenation and suppresses cycling hypoxia.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Squamous Cell; Cell Hypoxia; Electron Spin Resonance Spectroscopy; Female; Indoles; Magnetic Resonance Imaging; Mice; Mice, Inbred C3H; Neoplasm Transplantation; Neovascularization, Pathologic; Oxygen; Pyrroles; Sunitinib | 2011 |
Targeted systemic radiotherapy with scVEGF/177Lu leads to sustained disruption of the tumor vasculature and intratumoral apoptosis.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Apoptosis; Bevacizumab; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; Endothelial Cells; Female; Humans; Indoles; Lutetium; Mice; Mice, Inbred BALB C; Mice, Inbred ICR; Mice, SCID; Neovascularization, Pathologic; Pyrroles; Radioisotopes; Radiopharmaceuticals; Receptors, Vascular Endothelial Growth Factor; Sunitinib; Vascular Endothelial Growth Factor A | 2011 |
Blockade of TGF-β signaling by the TGFβR-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; DNA Damage; DNA Repair; Glioblastoma; Humans; Mesenchymal Stem Cells; Mice; Mice, Inbred BALB C; Mice, SCID; Microarray Analysis; Neoplasm Invasiveness; Neoplastic Stem Cells; Neovascularization, Pathologic; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrazoles; Pyrroles; Radiation Tolerance; Radiation-Sensitizing Agents; Receptor, Transforming Growth Factor-beta Type I; Receptors, Transforming Growth Factor beta; Signal Transduction; Smad2 Protein; Transforming Growth Factor beta; Xenograft Model Antitumor Assays | 2011 |
Copper dependence of angioproliferation in pulmonary arterial hypertension in rats and humans.
Topics: Animals; Caspases; Cell Division; Cells, Cultured; Chelating Agents; Copper; Diet; Endothelium, Vascular; Enzyme Activation; Humans; Hypertension, Pulmonary; Hypoxia; Immunohistochemistry; Indoles; Male; Microvessels; Molybdenum; Neovascularization, Pathologic; Pyrroles; Rats; Rats, Sprague-Dawley | 2012 |
HS-116, a novel phosphatidylinositol 3-kinase inhibitor induces apoptosis and suppresses angiogenesis of hepatocellular carcinoma through inhibition of the PI3K/AKT/mTOR pathway.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle; Cell Cycle Proteins; Cell Growth Processes; Cell Line, Tumor; Hep G2 Cells; Human Umbilical Vein Endothelial Cells; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Neovascularization, Pathologic; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyridines; Pyrroles; Signal Transduction; Sulfonamides; TOR Serine-Threonine Kinases | 2012 |
Hypoxia-inducible factor-1α inhibition by a pyrrolopyrazine metabolite of oltipraz as a consequence of microRNAs 199a-5p and 20a induction.
Topics: Cell Hypoxia; Cell Line, Tumor; Cell Movement; Cobalt; HT29 Cells; Humans; Hydrogen Peroxide; Hypoxia-Inducible Factor 1, alpha Subunit; Insulin; MicroRNAs; Neoplasm Invasiveness; Neovascularization, Pathologic; Pyrazines; Pyridazines; Pyrroles; Thiones; Thiophenes | 2012 |
HGF/c-Met pathway is one of the mediators of sunitinib-induced tumor cell type-dependent metastasis.
Topics: Angiogenesis Inhibitors; Animals; Breast Neoplasms; Cell Line, Tumor; Colorectal Neoplasms; Enzyme-Linked Immunosorbent Assay; Hepatocyte Growth Factor; Humans; Indoles; Lung Neoplasms; Lymphatic Metastasis; Mice; Mice, Nude; Neoplasm Metastasis; Neovascularization, Pathologic; Proto-Oncogene Proteins c-met; Pyrroles; Signal Transduction; Sunitinib | 2012 |
Is apparent diffusion coefficient reliable and accurate for monitoring effects of antiangiogenic treatment in a longitudinal study?
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Diffusion Magnetic Resonance Imaging; Female; Glioblastoma; Image Enhancement; Image Interpretation, Computer-Assisted; Indoles; Longitudinal Studies; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Pyrroles; Reproducibility of Results; Sensitivity and Specificity; Sunitinib; Treatment Outcome | 2012 |
Antitumor effect of vascular endothelial growth factor inhibitor sunitinib in preclinical models of hepatocellular carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Cycle; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Humans; Indoles; Liver Neoplasms; Male; Mice; Mice, SCID; Neovascularization, Pathologic; Pyrroles; Sunitinib; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2012 |
Combination of Temsirolimus and tyrosine kinase inhibitors in renal carcinoma and endothelial cell lines.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Drug Therapy, Combination; Human Umbilical Vein Endothelial Cells; Humans; Indoles; Kidney Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2012 |
Antiangiogenic agents: fueling cancer's hypoxic roots.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Cell Hypoxia; Humans; Indoles; Neoplasms; Neoplastic Stem Cells; Neovascularization, Pathologic; Pyrroles; Sunitinib | 2012 |
Cytotoxic effects of combination of oxidosqualene cyclase inhibitors with atorvastatin in human cancer cells.
Topics: Alkynes; Angiogenesis Inhibitors; Animals; Anticholesteremic Agents; Antineoplastic Agents; Atorvastatin; Brain; Carbamates; Cell Line, Tumor; Cell Proliferation; Cricetinae; Cyclohexanes; Drug Screening Assays, Antitumor; Drug Synergism; Endothelial Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intramolecular Transferases; Microsomes, Liver; Neovascularization, Pathologic; Pyrroles; Structure-Activity Relationship | 2012 |
Rapid angiogenesis onset after discontinuation of sunitinib treatment of renal cell carcinoma patients.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Apoptosis; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Female; Humans; Indoles; Male; Microvessels; Middle Aged; Neovascularization, Pathologic; Pyrroles; Retrospective Studies; Sunitinib | 2012 |
SU6668, a multiple tyrosine kinase inhibitor, inhibits progression of human malignant pleural mesothelioma in an orthotopic model.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Fibroblast Growth Factor 2; Humans; Indoles; Male; Mesothelioma; Mice; Mice, SCID; Neovascularization, Pathologic; Oxindoles; Pleural Effusion, Malignant; Pleural Neoplasms; Propionates; Protein Kinase Inhibitors; Pyrroles; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2012 |
Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antineoplastic Agents; Benzamides; Benzenesulfonates; Cell Line, Tumor; Disease Models, Animal; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Imatinib Mesylate; In Vitro Techniques; Indoles; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Nude; Neoplasm Metastasis; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperazines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2012 |
Effects of atorvastatin in the regulation of circulating EPCs and angiogenesis in traumatic brain injury in rats.
Topics: Animals; Atorvastatin; Brain Injuries; Endothelial Cells; Heptanoic Acids; Hippocampus; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Long-Term Potentiation; Male; Maze Learning; Neovascularization, Pathologic; Pyrroles; Rats; Rats, Wistar; Recovery of Function; Stem Cells | 2012 |
Evaluation of poly-mechanistic antiangiogenic combinations to enhance cytotoxic therapy response in pancreatic cancer.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Bevacizumab; Carcinoma, Pancreatic Ductal; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Female; Gemcitabine; Humans; Indoles; Mice; Mice, Nude; Mice, SCID; Neovascularization, Pathologic; Pancreatic Neoplasms; Poly(ADP-ribose) Polymerases; Pyrroles; Sunitinib; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Ambivalent effects of atorvastatin on angiogenesis, epidermal cell proliferation and tumorgenesis in animal models.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Atorvastatin; Cell Proliferation; Croton Oil; Epidermal Cells; Epidermis; Female; Heptanoic Acids; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mevalonic Acid; Mice; Neovascularization, Pathologic; Pyrroles; Rats; Rats, Wistar; Skin Neoplasms | 2012 |
Apricoxib, a novel inhibitor of COX-2, markedly improves standard therapy response in molecularly defined models of pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Synergism; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Metastasis; Neovascularization, Pathologic; Pancreatic Neoplasms; Pyrroles; Quinazolines; Sulfonamides | 2012 |
Targeting angiogenesis in metastatic breast cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Everolimus; Female; Fluorouracil; Humans; Indoles; Neoplasm Metastasis; Neovascularization, Pathologic; Niacinamide; Paclitaxel; Phenylurea Compounds; Pyrroles; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2012 |
The preventative effects of sunitinib malate observed in the course from non-castration to castration LNCaP xenograft prostate tumors.
Topics: Androgens; Animals; Apoptosis; Caspase 3; Cell Line, Tumor; Cell Proliferation; Humans; Indoles; Ki-67 Antigen; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Orchiectomy; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Receptors, Platelet-Derived Growth Factor; Sunitinib; Vascular Endothelial Growth Factor Receptor-2; von Willebrand Factor; Xenograft Model Antitumor Assays | 2012 |
Activation of alternate prosurvival pathways accounts for acquired sunitinib resistance in U87MG glioma xenografts.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Blotting, Western; Drug Resistance, Neoplasm; Fluorescent Antibody Technique; Glioma; Graft Survival; Humans; Indoles; Male; Mice; Mice, Nude; Microdialysis; Neoplasm Transplantation; Neovascularization, Pathologic; Phenotype; Phospholipase C gamma; Polymerase Chain Reaction; Pyrroles; Sunitinib | 2012 |
Sunitinib treatment does not improve blood supply but induces hypoxia in human melanoma xenografts.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Basement Membrane; Blood Vessels; Cell Hypoxia; Female; Humans; Indoles; Melanoma; Mice; Mice, Nude; Neovascularization, Pathologic; Pyrroles; Spheroids, Cellular; Sunitinib; Tumor Burden; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2012 |
Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Cell Hypoxia; Cell Line, Tumor; Drug Resistance, Neoplasm; Flow Cytometry; Glioblastoma; Humans; Immunohistochemistry; Indoles; Mesoderm; Mice; Mice, Nude; Myeloid Cells; Neovascularization, Pathologic; Phenotype; Pyrroles; Real-Time Polymerase Chain Reaction; Receptors, Vascular Endothelial Growth Factor; Stem Cells; Sunitinib; Tumor Microenvironment; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2012 |
Vascular endothelial growth factor signals through platelet-derived growth factor receptor β in meningiomas in vitro.
Topics: Angiogenic Proteins; Cell Proliferation; Humans; Indoles; Meningeal Neoplasms; Meningioma; Neovascularization, Pathologic; Phosphorylation; Piperazines; Proto-Oncogene Proteins c-sis; Pyrroles; Quinazolines; Receptor, Platelet-Derived Growth Factor beta; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sunitinib; Tumor Cells, Cultured; Tyrosine; Vascular Endothelial Growth Factor A; Xanthones | 2012 |
Sodium nitrite therapy rescues ischemia-induced neovascularization and blood flow recovery in hypertension.
Topics: Allopurinol; Angiotensin II; Animals; Arterial Pressure; Capillaries; Cyclic AMP; Cyclic GMP; Femoral Artery; Hindlimb; Hypertension; Indoles; Ischemia; Male; Mice; Mice, Inbred C57BL; Muscle, Skeletal; Neovascularization, Pathologic; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase Type III; Proto-Oncogene Proteins c-akt; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Regional Blood Flow; Sodium Nitrite; Xanthine Dehydrogenase | 2012 |
Deeper penetration into tumor tissues and enhanced in vivo antitumor activity of liposomal paclitaxel by pretreatment with angiogenesis inhibitor SU5416.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Colonic Neoplasms; Humans; Immunoenzyme Techniques; Indoles; Liposomes; Male; Mice; Mice, Inbred BALB C; Neovascularization, Pathologic; Paclitaxel; Pericytes; Polyethylene Glycols; Pyrroles; Solubility; Tumor Cells, Cultured; Vascular Endothelial Growth Factor Receptor-2 | 2012 |
Changes in circulating pro-angiogenic cytokines, other than VEGF, before progression to sunitinib therapy in advanced renal cell carcinoma patients.
Topics: Adult; Aged; Angiogenesis Inhibitors; Biomarkers, Tumor; Carcinoma, Renal Cell; Disease Progression; Enzyme-Linked Immunosorbent Assay; Female; Fibroblast Growth Factor 2; Follow-Up Studies; Hepatocyte Growth Factor; Humans; Indoles; Interleukin-6; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Neovascularization, Pathologic; Prognosis; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor A | 2013 |
Blockade of epidermal growth factor receptor signaling on tumor cells and tumor-associated endothelial cells for therapy of human carcinomas.
Topics: Animals; Antineoplastic Agents; Deoxycytidine; Endothelium, Vascular; ErbB Receptors; Gemcitabine; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Neovascularization, Pathologic; Paclitaxel; Pyrimidines; Pyrroles; Signal Transduction; Tumor Cells, Cultured | 2002 |
Blockade of the epidermal growth factor receptor signaling inhibits angiogenesis leading to regression of human renal cell carcinoma growing orthotopically in nude mice.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Renal Cell; Deoxycytidine; DNA-Binding Proteins; Down-Regulation; Endothelial Growth Factors; Enzyme Inhibitors; ErbB Receptors; Gemcitabine; Immunohistochemistry; In Situ Nick-End Labeling; Intercellular Signaling Peptides and Proteins; Kidney; Lung; Lymphokines; Mice; Mice, Nude; Neoplasm Metastasis; Neovascularization, Pathologic; Phosphorylation; Proliferating Cell Nuclear Antigen; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Signal Transduction; STAT3 Transcription Factor; Time Factors; Trans-Activators; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2002 |
Colorectal cancer: targeting metastasis and angiogenesis.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Colorectal Neoplasms; Disease Progression; Extracellular Matrix; Humans; Indoles; Matrix Metalloproteinases; Neoplasm Metastasis; Neovascularization, Pathologic; Pyrroles | 2002 |
Antiangiogenic effect by SU5416 is partly attributable to inhibition of Flt-1 receptor signaling.
Topics: 3T3 Cells; Angiogenesis Inhibitors; Animals; Cell Movement; Cells, Cultured; Chemotaxis; Collagen; DNA, Complementary; Dose-Response Relationship, Drug; Drug Combinations; Endothelium, Vascular; Extracellular Matrix Proteins; Humans; Immunoblotting; Indoles; Laminin; Male; Mice; Monocytes; Myosin Heavy Chains; Neovascularization, Pathologic; Nonmuscle Myosin Type IIB; Phosphorylation; Placenta Growth Factor; Pregnancy Proteins; Protein-Tyrosine Kinases; Proteoglycans; Pyrroles; Transfection; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2002 |
Comparative study of isoflavone, quinoxaline and oxindole families of anti-angiogenic agents.
Topics: Angiogenesis Inhibitors; Endothelium, Vascular; Humans; Indoles; Isoflavones; Neoplasms; Neovascularization, Pathologic; Oxindoles; Propionates; Pyrroles; Quinoxalines | 2002 |
Interleukin-2 and cancer: critical analysis of results, problems and expectations.
Topics: Cytokines; Humans; Immunotherapy; Indoles; Interleukin-2; Neoplasm Metastasis; Neoplasms; Neovascularization, Pathologic; Oxindoles; Propionates; Protein-Tyrosine Kinases; Pyrroles; Receptors, Interleukin-2 | 2003 |
Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Blood Vessels; Carcinoma, Islet Cell; Endothelium, Vascular; Female; Indoles; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neovascularization, Pathologic; Oxindoles; Pericytes; Platelet-Derived Growth Factor; Propionates; Protein-Tyrosine Kinases; Pyrroles; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor | 2003 |
Influence of VEGF-R2 inhibition on MMP secretion and motility of microvascular human cerebral endothelial cells (HCEC).
Topics: Angiogenesis Inhibitors; Brain Neoplasms; Cell Movement; Cerebral Cortex; Endothelium, Vascular; Enzyme-Linked Immunosorbent Assay; Glioblastoma; Humans; Immunoenzyme Techniques; In Vitro Techniques; Indoles; Interleukin-10; Matrix Metalloproteinases; Microcirculation; Neovascularization, Pathologic; Protein-Tyrosine Kinases; Pyrroles; Spheroids, Cellular; Tumor Cells, Cultured; Umbilical Veins; Vascular Endothelial Growth Factor Receptor-2 | 2003 |
SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro.
Topics: Angiogenesis Inhibitors; Cell Division; Cells, Cultured; Dose-Response Relationship, Radiation; Endothelial Growth Factors; Endothelium, Vascular; Fibroblast Growth Factor 2; Humans; Indoles; Intercellular Signaling Peptides and Proteins; Kinetics; Lymphokines; Male; Neoplasm Invasiveness; Neovascularization, Pathologic; Oxindoles; Particle Accelerators; Propionates; Prostatic Neoplasms; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; Tumor Cells, Cultured; Umbilical Veins; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; X-Rays | 2003 |
Combining antiangiogenic agents with metronomic chemotherapy enhances efficacy against late-stage pancreatic islet carcinomas in mice.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Islet Cell; Chronotherapy; Indoles; Matrix Metalloproteinase Inhibitors; Mice; Neovascularization, Pathologic; Pancreatic Neoplasms; Phenylalanine; Protease Inhibitors; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Thiophenes | 2002 |
SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Lewis Lung; Combined Modality Therapy; Endothelium, Vascular; Glioblastoma; Humans; Indoles; Mice; Mice, Inbred C57BL; Neoplasm Recurrence, Local; Neoplasms, Experimental; Neovascularization, Pathologic; Pyrroles; Receptor Protein-Tyrosine Kinases; Sunitinib | 2003 |
SU5416 selectively impairs angiogenesis to induce prostate cancer-specific apoptosis.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Cell Differentiation; Disease Models, Animal; Disease Progression; Drug Evaluation, Preclinical; Gene Expression Regulation, Neoplastic; Indoles; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microcirculation; Neovascularization, Pathologic; Prostatic Neoplasms; Protein-Tyrosine Kinases; Pyrroles; Up-Regulation; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2003 |
SU6668 in idiopathic myelofibrosis--a rational therapeutic approach targeting several tyrosine kinases of importance for the myeloproliferation and the development of bone marrow fibrosis and angiogenesis.
Topics: Bone Marrow; Enzyme Inhibitors; Humans; Indoles; Models, Biological; Neovascularization, Pathologic; Oxindoles; Primary Myelofibrosis; Propionates; Pyrroles; Receptor Protein-Tyrosine Kinases | 2003 |
Statin use is associated with enhanced collateralization of severely diseased coronary arteries.
Topics: Aged; Aspirin; Atorvastatin; Calcium Channels; Collateral Circulation; Coronary Angiography; Coronary Disease; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Multivariate Analysis; Neovascularization, Pathologic; Pyrroles; Retrospective Studies | 2003 |
Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms.
Topics: Animals; Apoptosis; Cell Survival; Hypoxia; Indoles; Microcirculation; Models, Biological; Neoplasms; Neovascularization, Pathologic; Oxindoles; Pericytes; Platelet-Derived Growth Factor; Propionates; Pyrroles; Receptor, Platelet-Derived Growth Factor beta; Signal Transduction; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2004 |
Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Division; Cell Movement; Cell Survival; Drug Synergism; Endostatins; Endothelium, Vascular; Female; Glioblastoma; Humans; Indoles; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Mice, SCID; Neoplasms; Neovascularization, Pathologic; Prostatic Neoplasms; Pyrroles; Ultrasonography; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2003 |
In vivo assessment of antiangiogenic activity of SU6668 in an experimental colon carcinoma model.
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Colonic Neoplasms; Contrast Media; Humans; Immunohistochemistry; Indoles; Magnetic Resonance Imaging; Mice; Mice, Nude; Models, Statistical; Neoplasm Transplantation; Neovascularization, Pathologic; Oxindoles; Permeability; Platelet Endothelial Cell Adhesion Molecule-1; Propionates; Protein-Tyrosine Kinases; Pyrroles; Time Factors | 2004 |
Hypoxia increases resistance of human pancreatic cancer cells to apoptosis induced by gemcitabine.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Blotting, Western; Butadienes; Cell Division; Cell Line, Tumor; Chromones; Deoxycytidine; Dose-Response Relationship, Drug; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Gemcitabine; Humans; Hypoxia; Mitogen-Activated Protein Kinases; Morpholines; Neovascularization, Pathologic; NF-kappa B; Nitriles; Oxygen; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Signal Transduction; Sp1 Transcription Factor; Time Factors; Tyrosine | 2004 |
Liver regeneration in FGF-2-deficient mice: VEGF acts as potential functional substitute for FGF-2.
Topics: Angiogenesis Inhibitors; Animals; Fibroblast Growth Factor 2; Hepatectomy; Homozygote; Indoles; Injections, Intraperitoneal; Liver Regeneration; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Neovascularization, Pathologic; Pyrroles; RNA, Messenger; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2004 |
Antiangiogenic versus cytotoxic therapeutic approaches to human pancreas cancer: an experimental study with a vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor and gemcitabine.
Topics: Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Division; Cell Line; Cell Line, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Endothelial Cells; Female; Gemcitabine; Humans; Immunohistochemistry; Indoles; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Pancreatic Neoplasms; Placenta; Pregnancy; Protein Kinase Inhibitors; Pyrroles; Time Factors; Tissue Culture Techniques; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2004 |
SU5416 inhibited VEGF and HIF-1alpha expression through the PI3K/AKT/p70S6K1 signaling pathway.
Topics: Binding Sites; Blotting, Northern; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunoblotting; Indoles; Luciferases; Neovascularization, Pathologic; Ovarian Neoplasms; Phosphatidylinositol 3-Kinases; Phosphorylation; Plasmids; Protein Binding; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Pyrroles; Ribosomal Protein S6 Kinases, 70-kDa; RNA; RNA, Messenger; Signal Transduction; Tetrazolium Salts; Thiazoles; Time Factors; Transcription Factors; Transcriptional Activation; Transfection; Up-Regulation; Vascular Endothelial Growth Factor A | 2004 |
Triple combination of irradiation, chemotherapy (pemetrexed), and VEGFR inhibition (SU5416) in human endothelial and tumor cells.
Topics: Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Combined Modality Therapy; Endothelial Cells; Glutamates; Guanine; Humans; Indoles; Neoplasms; Neovascularization, Pathologic; Pemetrexed; Protein-Tyrosine Kinases; Pyrroles; Tumor Stem Cell Assay | 2004 |
The multi-targeted kinase inhibitor SU5416 inhibits small cell lung cancer growth and angiogenesis, in part by blocking Kit-mediated VEGF expression.
Topics: Animals; Carcinoma, Small Cell; Drug Resistance, Neoplasm; Female; Humans; Indoles; Lung Neoplasms; Mice; Mice, Nude; Neovascularization, Pathologic; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrroles; Transplantation, Heterologous; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A | 2004 |
A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.
Topics: Adenoma, Islet Cell; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Clinical Protocols; Cyclophosphamide; Disease Models, Animal; Endothelial Cells; Imatinib Mesylate; Indoles; Mice; Mice, Transgenic; Neovascularization, Pathologic; Pancreatic Neoplasms; Pericytes; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Remission Induction; Sunitinib | 2005 |
The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Blood Vessels; Carcinoma, Lewis Lung; Cell Movement; Cells, Cultured; Endothelium, Vascular; Humans; Indoles; Intracellular Signaling Peptides and Proteins; Mice; Mice, Inbred C57BL; Neoplasm Metastasis; Neovascularization, Pathologic; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Secondary Prevention; Sunitinib; Umbilical Cord | 2004 |
Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668.
Topics: Adult; Aged; Aged, 80 and over; Animals; Apoptosis; Dose-Response Relationship, Drug; Endothelium, Vascular; Female; Humans; Indoles; Male; Mice; Mice, Nude; Middle Aged; Neovascularization, Pathologic; Oxindoles; Pancreatic Neoplasms; Phosphorylation; Propionates; Pyrroles; Receptor, Platelet-Derived Growth Factor beta; Transplantation, Heterologous; Vascular Endothelial Growth Factor Receptor-2 | 2005 |
Combined inhibition of vascular endothelial growth factor and platelet-derived growth factor signaling: effects on the angiogenesis, microcirculation, and growth of orthotopic malignant gliomas.
Topics: Animals; Apoptosis; Brain; Brain Neoplasms; Cell Division; Cell Line, Tumor; Cell Transformation, Neoplastic; Glioma; Indoles; Mice; Mice, Nude; Microcirculation; Microscopy, Fluorescence; Microscopy, Video; Neoplasm Transplantation; Neovascularization, Pathologic; Oxindoles; Platelet-Derived Growth Factor; Propionates; Protein-Tyrosine Kinases; Pyrroles; Rats; Receptor, Platelet-Derived Growth Factor beta; Signal Transduction; Transplantation, Heterologous; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2005 |
Angiogenesis inhibitor Z24 induces endothelial cell apoptosis and suppresses tumor growth and metastasis.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Cell Line; Cell Line, Tumor; Colonic Neoplasms; Endothelium, Vascular; Humans; Lung Neoplasms; Male; Mesylates; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Neovascularization, Pathologic; Pyrroles; Transplantation, Heterologous | 2005 |
Inhibition of VEGF receptor-2 decreases the development of hyperdynamic splanchnic circulation and portal-systemic collateral vessels in portal hypertensive rats.
Topics: Angiogenesis Inhibitors; Animals; Arterioles; Collateral Circulation; Hemodynamics; Hypertension, Portal; Indoles; Male; Neovascularization, Pathologic; Platelet Endothelial Cell Adhesion Molecule-1; Portal System; Portal Vein; Protein Kinase Inhibitors; Pyrroles; Rats; Rats, Sprague-Dawley; Regional Blood Flow; Splanchnic Circulation; Vascular Endothelial Growth Factor Receptor-2; Vascular Resistance | 2005 |
Sonographic depiction of changes of tumor vascularity in response to various therapies.
Topics: Angiogenesis Inhibitors; Animals; Combined Modality Therapy; In Situ Nick-End Labeling; Indoles; Lung Neoplasms; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; Pyrroles; Sunitinib; Ultrasonography, Doppler, Color; Vascular Endothelial Growth Factor A | 2005 |
Early antiangiogenic activity of SU11248 evaluated in vivo by dynamic contrast-enhanced magnetic resonance imaging in an experimental model of colon carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Colonic Neoplasms; Contrast Media; Gadolinium DTPA; HT29 Cells; Humans; Image Enhancement; Indoles; Magnetic Resonance Imaging; Mice; Mice, Nude; Neovascularization, Pathologic; Pyrroles; Reproducibility of Results; Sensitivity and Specificity; Sunitinib; Treatment Outcome; Xenograft Model Antitumor Assays | 2005 |
Combined inhibition of vascular endothelial growth factor (VEGF), fibroblast growth factor and platelet-derived growth factor, but not inhibition of VEGF alone, effectively suppresses angiogenesis and vessel maturation in endometriotic lesions.
Topics: Angiogenesis Inhibitors; Animals; Capillaries; Cricetinae; Endometriosis; Endometrium; Female; Fibroblast Growth Factors; Indoles; Mesocricetus; Neovascularization, Pathologic; Oxindoles; Platelet-Derived Growth Factor; Propionates; Protein Kinase Inhibitors; Pyrroles; Uterine Diseases; Vascular Endothelial Growth Factor A | 2006 |
Antiangiogenic agent SU6668 suppresses the tumor growth of xenografted A-431 cells.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Squamous Cell; Endothelium, Vascular; Esophageal Neoplasms; Humans; Indoles; Mice; Mice, SCID; Neoplasm Transplantation; Neovascularization, Pathologic; Oxindoles; Platelet Endothelial Cell Adhesion Molecule-1; Propionates; Pyrroles; Xenograft Model Antitumor Assays | 2006 |
Molecular strategies targeting the host component of cancer to enhance tumor response to radiation therapy.
Topics: Angiogenesis Inhibitors; Animals; Class I Phosphatidylinositol 3-Kinases; Combined Modality Therapy; Endothelial Cells; Endothelium, Vascular; Enzyme Activation; Enzyme Inhibitors; Fibroblast Growth Factor 2; Humans; Indoles; Mice; Neoplasms; Neovascularization, Pathologic; Oxindoles; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Propionates; Pyrroles; Quinazolines; Radiation Tolerance; Receptor Protein-Tyrosine Kinases; Sunitinib; Vascular Endothelial Growth Factor A | 2006 |
Antiangiogenic combination tumor therapy blocking alpha(v)-integrins and VEGF-receptor-2 increases therapeutic effects in vivo.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Cricetinae; Disease Progression; Indoles; Integrin alphaV; Male; Mesocricetus; Microcirculation; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Pyrroles; Vascular Endothelial Growth Factor Receptor-2 | 2006 |
The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesis.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line; Cell Line, Tumor; Cells, Cultured; Collagen; Dose-Response Relationship, Drug; Drug Combinations; Drug Synergism; Drug Therapy, Combination; Endothelial Cells; Female; Immunohistochemistry; Indoles; Laminin; Mice; Mice, Nude; Myocytes, Smooth Muscle; Neovascularization, Pathologic; Neovascularization, Physiologic; Oxindoles; Paclitaxel; Platelet Endothelial Cell Adhesion Molecule-1; Propionates; Protein-Tyrosine Kinases; Proteoglycans; Pyrroles; Xenograft Model Antitumor Assays | 2006 |
Mild increases in portal pressure upregulate vascular endothelial growth factor and endothelial nitric oxide synthase in the intestinal microcirculatory bed, leading to a hyperdynamic state.
Topics: Angiogenesis Inhibitors; Animals; Endothelium, Vascular; Hypertension, Portal; Indoles; Intestinal Mucosa; Intestines; Jejunum; Male; Microcirculation; Neovascularization, Pathologic; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Portal Pressure; Pyrroles; Rats; Up-Regulation; Vascular Endothelial Growth Factor A; Vasodilation | 2006 |
[Effect of angiogenesis inhibitor SU6668 on the growth and metastasis of gastric cancer in SCID mice].
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Cell Line, Tumor; Drug Synergism; Fluorouracil; Humans; Indoles; Liver Neoplasms; Male; Mice; Mice, SCID; Neoplasm Transplantation; Neoplasms, Experimental; Neovascularization, Pathologic; Oxindoles; Propionates; Pyrroles; Stomach Neoplasms | 2006 |
Sunitinib malate and sorafenib may be beneficial at the treatment of advanced bladder cancer due to their anti-angiogenic effects.
Topics: Angiogenesis Inhibitors; Benzenesulfonates; Humans; Indoles; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Sorafenib; Sunitinib; Urinary Bladder Neoplasms | 2007 |
Modulation of angiogenic phenotype alters tumorigenicity in rat ovarian epithelial cells.
Topics: Angiogenesis Inhibitors; Animals; Cell Growth Processes; Cell Transformation, Neoplastic; Endostatins; Female; Indoles; Neovascularization, Pathologic; Ovarian Neoplasms; Pyrroles; Rats; Transfection; Vascular Endothelial Growth Factor A | 2007 |
[Anti-angiogenetic agents for solid tumors].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Cell Transformation, Neoplastic; Humans; Indoles; Neoplasms; Neovascularization, Pathologic; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor A | 2007 |
Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Prognosis; Prospective Studies; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Sorafenib; Sunitinib; Survival Rate; Vascular Endothelial Growth Factor A | 2007 |
Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma.
Topics: Angiogenesis Inhibitors; Animals; Blotting, Western; Brain; Brain Neoplasms; Cell Line, Tumor; Flow Cytometry; Focal Adhesion Protein-Tyrosine Kinases; Glioblastoma; Humans; Immunohistochemistry; Immunoprecipitation; Indoles; Mice; Mice, Nude; Neoplasm Invasiveness; Neoplasm Transplantation; Neovascularization, Pathologic; Organ Culture Techniques; Phosphorylation; Pyrroles; src-Family Kinases; Sunitinib; Xenograft Model Antitumor Assays | 2007 |
Regression of brain metastases of renal cell carcinoma with antiangiogenic therapy.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Middle Aged; Neovascularization, Pathologic; Pyrroles; Sunitinib; Treatment Outcome | 2008 |
Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma.
Topics: Animals; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Movement; Cell Survival; Endoplasmic Reticulum; Heat-Shock Proteins; Humans; Lactones; Mice; Multiple Myeloma; Neovascularization, Pathologic; NF-kappa B; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Pyrroles; Xenograft Model Antitumor Assays | 2008 |
Combining agents that target the tumor microenvironment improves the efficacy of anticancer therapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Cyclophosphamide; Endothelial Cells; Female; Fluorescent Antibody Technique; Humans; Indoles; Lenalidomide; Mice; Neoplasms, Experimental; Neovascularization, Pathologic; Pyrroles; Rats; Sunitinib; Thalidomide; Xenograft Model Antitumor Assays | 2008 |
Rare case of hemangiopericytoma responds to sunitinib.
Topics: Angiogenesis Inhibitors; Bone Neoplasms; Hemangiopericytoma; Humans; Indoles; Lung Neoplasms; Male; Maxillary Sinus Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Pelvic Neoplasms; Protein Kinase Inhibitors; Pyrroles; Radiography; Rare Diseases; Sunitinib | 2008 |
Impact of angiogenesis inhibition by sunitinib on tumor distribution of temozolomide.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Blotting, Western; Collagen; Collagen Type IV; Dacarbazine; Drug Combinations; Glioma; Immunoenzyme Techniques; Indoles; Laminin; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Platelet Endothelial Cell Adhesion Molecule-1; Proteoglycans; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sunitinib; Temozolomide; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2008 |
Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Endothelial Cells; Flow Cytometry; Humans; Immunohistochemistry; Indoles; Mice; Mice, Nude; Neoplasms; Neovascularization, Pathologic; Oxindoles; Propionates; Protein Kinase Inhibitors; Pyrroles; Radiation-Sensitizing Agents; Radiotherapy; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Reverse Transcriptase Polymerase Chain Reaction; Xenograft Model Antitumor Assays | 2008 |
LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis.
Topics: Animals; Anoikis; Antimetabolites, Antineoplastic; Apoptosis; Cell Movement; Deoxycytidine; Drug Therapy, Combination; Gemcitabine; Humans; Lung Neoplasms; Mice; Mice, Inbred C57BL; Mice, Nude; Neoplasm Invasiveness; Neovascularization, Pathologic; Pancreatic Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrazoles; Pyrroles; Receptor, Transforming Growth Factor-beta Type I; Receptor, Transforming Growth Factor-beta Type II; Receptors, Transforming Growth Factor beta; Ribonucleotide Reductases; Signal Transduction; Smad2 Protein; Survival Rate; Transforming Growth Factor beta; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2008 |
Inhibition of insulin-like growth factor-I receptor (IGF-IR) using NVP-AEW541, a small molecule kinase inhibitor, reduces orthotopic pancreatic cancer growth and angiogenesis.
Topics: Angiogenesis Inhibitors; Animals; Cell Communication; Cell Movement; Cell Proliferation; Humans; Immunohistochemistry; Mice; Mice, Inbred BALB C; Neovascularization, Pathologic; Pancreatic Neoplasms; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Receptor, IGF Type 1 | 2008 |
Synthesis of 6-aminouracils and pyrrolo[2,3-d]pyrimidine-2,4-diones and their inhibitory effect on thymidine phosphorylase.
Topics: Antimetabolites, Antineoplastic; Cell Division; Drug Design; Enzyme Inhibitors; Female; Humans; Neovascularization, Pathologic; Pregnancy; Pyrimidinones; Pyrroles; Thymidine Phosphorylase; Tumor Cells, Cultured; Uracil | 1997 |
Synthesis and binding mode of heterocyclic analogues of suramin inhibiting the human basic fibroblast growth factor.
Topics: 3T3 Cells; Allantois; Animals; Antineoplastic Agents; Chorion; Drug Screening Assays, Antitumor; Fibroblast Growth Factor 2; Humans; In Vitro Techniques; Ligands; Mice; Models, Molecular; Naphthalenes; Neovascularization, Pathologic; Pyrazoles; Pyrroles; Structure-Activity Relationship; Suramin | 1998 |
SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types.
Topics: 3T3 Cells; Animals; Catalysis; Cell Division; Endothelium, Vascular; Enzyme Inhibitors; Glioma; Humans; Indoles; Mice; Neoplasms, Experimental; Neovascularization, Pathologic; Protein-Tyrosine Kinases; Pyrroles; Rats; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Receptors, Mitogen; Receptors, Vascular Endothelial Growth Factor; Tumor Cells, Cultured | 1999 |
Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis.
Topics: Animals; Apoptosis; Colonic Neoplasms; Endothelium; Fluorescent Antibody Technique; In Situ Nick-End Labeling; Indoles; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Neovascularization, Pathologic; Pyrroles; Random Allocation; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor; Tumor Cells, Cultured | 1999 |
Inhibition of angiogenesis by blocking activation of the vascular endothelial growth factor receptor 2 leads to decreased growth of neurogenic sarcomas.
Topics: Angiogenesis Inhibitors; Animals; Chemotherapy, Adjuvant; Dose-Response Relationship, Drug; Endothelial Growth Factors; Enzyme Inhibitors; Indoles; Lymphokines; Male; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Transplantation; Neovascularization, Pathologic; Neurofibromatosis 1; Neurons; Pyrroles; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor; Sarcoma; Time Factors; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 1999 |
Synthesis and characterization of polypyrrole-hyaluronic acid composite biomaterials for tissue engineering applications.
Topics: Animals; Biocompatible Materials; Biomedical Engineering; Blood Vessels; Bone Regeneration; Electric Conductivity; Hyaluronic Acid; Inflammation; Male; Microscopy, Electron, Scanning; Neovascularization, Pathologic; Nerve Regeneration; PC12 Cells; Polymers; Prostheses and Implants; Pyrroles; Rats; Rats, Sprague-Dawley | 2000 |
Vascular endothelial growth factor in human colon cancer: biology and therapeutic implications.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Cell Division; Colonic Neoplasms; Disease Models, Animal; Endothelial Growth Factors; Endothelium, Vascular; Enzyme Inhibitors; Humans; Indoles; Liver Neoplasms; Lymphokines; Mice; Neoplasm Metastasis; Neovascularization, Pathologic; Prognosis; Protein Isoforms; Protein-Tyrosine Kinases; Pyrroles; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Receptors, Mitogen; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2000 |
Measuring VEGF-Flk-1 activity and consequences of VEGF-Flk-1 targeting in vivo using intravital microscopy: clinical applications.
Topics: Analysis of Variance; Angiogenesis Inhibitors; Animals; Disease Models, Animal; Endothelial Growth Factors; Enzyme Inhibitors; Glioblastoma; Indoles; Lymphokines; Male; Mice; Mice, Nude; Microcirculation; Microscopy, Fluorescence; Microscopy, Video; Neoplasm Transplantation; Neovascularization, Pathologic; Protein Isoforms; Protein-Tyrosine Kinases; Pyrroles; Rats; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Receptors, Mitogen; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Skin Neoplasms; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2000 |
Targeting angiogenesis inhibits tumor infiltration and expression of the pro-invasive protein SPARC.
Topics: Angiogenesis Inhibitors; Animals; Biomarkers, Tumor; Cell Division; Cell Movement; Dimethyl Sulfoxide; Dose-Response Relationship, Drug; Enzyme Inhibitors; Glioma; Immunohistochemistry; Indoles; Male; Mice; Mice, Nude; Microscopy, Fluorescence; Microscopy, Video; Neoplasm Invasiveness; Neoplasm Transplantation; Neovascularization, Pathologic; Osteonectin; Pyrroles; Rats; Solvents; Time Factors; Tumor Cells, Cultured | 2000 |
Inhibition of tumor growth, angiogenesis, and microcirculation by the novel Flk-1 inhibitor SU5416 as assessed by intravital multi-fluorescence videomicroscopy.
Topics: Animals; Antineoplastic Agents; Enzyme Inhibitors; Glioblastoma; Indoles; Male; Mice; Mice, Nude; Microcirculation; Neovascularization, Pathologic; Pyrroles; Rats; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor | 1999 |
SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors.
Topics: 3T3 Cells; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Cell Division; Crystallography, X-Ray; Dose-Response Relationship, Drug; Endothelium, Vascular; Enzyme Inhibitors; Female; Humans; Indoles; Kinetics; Mice; Mice, Inbred BALB C; Mice, Nude; Models, Molecular; Neoplasm Transplantation; Neoplasms, Experimental; Neovascularization, Pathologic; Oxindoles; Propionates; Protein-Tyrosine Kinases; Pyrroles; Receptor Protein-Tyrosine Kinases; Receptor, Platelet-Derived Growth Factor beta; Receptors, Fibroblast Growth Factor; Receptors, Growth Factor; Receptors, Mitogen; Receptors, Vascular Endothelial Growth Factor; Transplantation, Heterologous; Tumor Cells, Cultured | 2000 |
The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function.
Topics: 3T3 Cells; Angiogenesis Inhibitors; Animals; Cell Division; Cell Membrane; Cell Separation; Cells, Cultured; Culture Media, Serum-Free; Dose-Response Relationship, Drug; Endothelium, Vascular; Epitopes; Female; Flow Cytometry; Humans; Indoles; Kinetics; Mice; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Neoplasm Transplantation; Neovascularization, Pathologic; Phosphorylation; Protein Binding; Protein-Tyrosine Kinases; Pyrroles; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Time Factors; Tumor Cells, Cultured; Umbilical Cord | 2000 |
Tyrosine kinase inhibition of multiple angiogenic growth factor receptors improves survival in mice bearing colon cancer liver metastases by inhibition of endothelial cell survival mechanisms.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Cell Division; Cell Survival; Colonic Neoplasms; Endothelium, Vascular; Indoles; Liver Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Neovascularization, Pathologic; Oxindoles; Propionates; Pyrroles; Receptor Protein-Tyrosine Kinases; Receptors, Fibroblast Growth Factor; Receptors, Growth Factor; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor | 2001 |
Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy.
Topics: Angiogenesis Inhibitors; Animals; Cell Survival; Dose-Response Relationship, Radiation; Endothelial Growth Factors; Endothelium, Vascular; Enzyme Inhibitors; Glioblastoma; Indoles; Lymphokines; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; Pyrroles; Radiation Tolerance; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2001 |
In vivo intracellular signaling as a marker of antiangiogenic activity.
Topics: Androstadienes; Angiogenesis Inhibitors; Biomarkers, Tumor; Blotting, Western; Endothelial Growth Factors; Endothelium, Vascular; Enzyme Activation; Enzyme Inhibitors; Flavonoids; Fluorescent Antibody Technique; Humans; Indoles; Liver Neoplasms; Lymphokines; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase Kinases; Neovascularization, Pathologic; Oxindoles; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Propionates; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Pyrroles; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; Wortmannin | 2001 |
Statins have biphasic effects on angiogenesis.
Topics: Animals; Apolipoproteins E; Apoptosis; Atorvastatin; Carcinoma, Lewis Lung; Cell Differentiation; Cell Division; Cell Movement; Cells, Cultured; Dose-Response Relationship, Drug; Endothelial Growth Factors; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lymphokines; Mice; Mice, Inbred C57BL; Mice, Knockout; Neovascularization, Pathologic; Neovascularization, Physiologic; Polyisoprenyl Phosphates; Pyridines; Pyrroles; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2002 |
Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Division; Deoxycytidine; Endothelium, Vascular; ErbB Receptors; Gemcitabine; Humans; Immunohistochemistry; Male; Mice; Mice, Nude; Neoplasm Metastasis; Neovascularization, Pathologic; Pancreatic Neoplasms; Phthalazines; Pyridines; Pyrimidines; Pyrroles; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Xenograft Model Antitumor Assays | 2002 |
Inhibition of vascular endothelial growth factor-associated tyrosine kinase activity with SU5416 blocks sprouting in the microvascular endothelial cell spheroid model of angiogenesis.
Topics: Angiogenesis Inhibitors; Animals; Cell Differentiation; Cell Division; Cells, Cultured; Collagen; Dose-Response Relationship, Drug; Drug Combinations; Endothelial Growth Factors; Endothelium, Vascular; Enzyme Inhibitors; Extracellular Matrix Proteins; Fibroblast Growth Factor 2; Indoles; Laminin; Lymphokines; Mice; Myosin Heavy Chains; Neovascularization, Pathologic; Nonmuscle Myosin Type IIB; Platelet Endothelial Cell Adhesion Molecule-1; Protein-Tyrosine Kinases; Proteoglycans; Pyrroles; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor; Umbilical Cord; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factors | 2002 |
CHS 828 inhibits neuroblastoma growth in mice alone and in combination with antiangiogenic drugs.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Division; Cyanides; Cyclohexanes; Guanidines; Humans; Indoles; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Neuroblastoma; O-(Chloroacetylcarbamoyl)fumagillol; Pyrroles; Remission Induction; Sesquiterpenes; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2002 |